

CITATION REPORT

List of articles citing

EGFR antagonists in cancer treatment

DOI: 10.1056/nejmra0707704

New England Journal of Medicine, 2008, 358, 1160-74.

Source: <https://exaly.com/paper-pdf/44054362/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1742	Targeted imaging of colorectal dysplasia in living mice with fluorescence microendoscopy. 2011 , 2, 981		
1741	Shape evolution of lead telluride and selenide nanostructures under different hydrothermal synthesis conditions. 2006 , 6, 1050-3		41
1740	[Cutaneous reactions to molecular targeted therapies]. 2008 , 59, 814-20		5
1739	Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside. 2008 , 43, 905-11		38
1738	KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. 2008 , 453, 417-31		241
1737	Pan-HER biologics (Hermodulins) for the treatment of cancer. 2008 , 69, 472-479		
1736	Effector mechanisms of therapeutic antibodies against ErbB receptors. 2008 , 20, 436-43		38
1735	Skin toxicity of anti-cancer therapy. 2008 , 6, 959-77		16
1734	Hauttoxizität durch antitumorale Therapie. 2008 , 6, no-no		
1733	Predicting the response to targeted therapy in metastatic colorectal cancer. 2008 , 4, 208-217		
1732	A glimmer of light for neuropsychiatric disorders. 2008 , 455, 890-3		75
1731	The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. 2008 , 99, 341-9		72
1730	Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs. 2008 , 99, 473-80		18
1729	Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. 2008 , 99, 455-8		48
1728	Decreased survival in EGFR gene amplified vulvar carcinoma. 2008 , 111, 289-97		46
1727	Cutaneous vasculitis in breast cancer treated with chemotherapy. 2008 , 129, 3-9		32
1726	Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia. 2008 , 81, 344-53		25

1725	The role of targeting mammalian target of rapamycin in lung cancer. 2008 , 9, 340-5	38
1724	Receptor tyrosine kinase inhibitors in thyroid cancer. 2008 , 22, 1023-38	31
1723	Molecular biology of head and neck cancer: risks and pathways. 2008 , 22, 1099-124, vii	52
1722	Lung cancer. <i>New England Journal of Medicine</i> , 2008 , 359, 1367-80	59.2 1920
1721	KRAS mutations predict response to EGFR inhibitors. 2008 , 8, 413-8	95
1720	First-line combination treatment of colorectal cancer with hepatic metastases: choosing a targeted agent. 2008 , 34 Suppl 2, S3-7	73
1719	Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. 2008 , 9, 962-72	623
1718	Lung cancer: moving forward with tailored strategies. 2008 , 9, 1116-7	3
1717	Novel acquisitions on the immunoprotective roles of the EGF receptor in the skin. 2008 , 3, 525-527	17
1716	EGFR inhibition as a therapy for head and neck squamous cell carcinoma. 2008 , 17, 1517-31	39
1715	Photodynamic targeting of EGFR does not predict the treatment outcome in combination with the EGFR tyrosine kinase inhibitor Tyrphostin AG1478. 2008 , 7, 1032-40	13
1714	Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-, Akt-, and NF-kappa B-dependent pathway. 2008 , 181, 8441-9	31
1713	Androgens and epithelial ovarian cancer: What's the connection?. 2008 , 7, 1712-6	9
1712	EGF receptor variant III as a target antigen for tumor immunotherapy. 2008 , 7, 977-85	57
1711	NEU3 sialidase strictly modulates GM3 levels in skeletal myoblasts C2C12 thus favoring their differentiation and protecting them from apoptosis. 2008 , 283, 36265-71	42
1710	HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. 2008 , 7, 2589-98	92
1709	EGFR-targeting agents in oncology. 2008 , 18, 889-901	16
1708	Tissue Localization of Therapy Targets in Cancer: Immunohistochemistry and Beyond. 2008 , 39, 688-691	0

1707	Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. 2008 , 14, 5069-80	127
1706	ErbB antagonists patenting: "playing chess with cancer". 2008 , 2, 181-7	5
1705	14-3-3sigma Modulates pancreatic cancer cell survival and invasiveness. 2008 , 14, 7614-23	51
1704	Treatment of non-small cell lung cancer, advanced disease, with erlotinib in 2(nd) and 3(rd) lines. Two cases report. 2008 , 14 Suppl 3, S53-60	
1703	Long survival with erlotinib as second line treatment in non-small cell lung cancer. 2008 , 14 Suppl 3, S85-8	
1702	Cytokines as potential tumour markers. 2008 , 2, 691-711	12
1701	Delivery of siRNA to the target cell cytoplasm: photochemical internalization facilitates endosomal escape and improves silencing efficiency, in vitro and in vivo. 2008 , 14, 3686-97	37
1700	Erlotinib in non-small cell lung cancer's second line treatment. Clinical case. 2008 , 14 Suppl 3, S79-83	
1699	Molecularly targeted therapy for hepatocellular carcinoma. 2008 , 49, 133-144	
1698	Evolving role of cetuximab in the treatment of colorectal cancer. 2009 , Volume 1, 79-88	3
1697	Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy. 2009 , 419	
1696	[Prognostic role of KRAS mutation in colorectal cancer]. 2009 , 96 Suppl, S23-30	1
1695	[The potential of monoclonal antibodies in cancer : established trastuzumab and cetuximab and promising targets IGF-1R and c-MET]. 2009 , 25, 1090-8	0
1694	Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy. 2009 , 2009, 831626	18
1693	Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. 2009 , 2009, 567486	85
1692	Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept. 2009 , 2009, 804108	27
1691	Gefitinib in combination with gemcitabine and carboplatin in never smokers with non-small cell lung carcinoma: a retrospective analysis. 2009 , 4, 988-93	3
1690	Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. 2009 , 4, e7746	68

1689	Mammary-derived growth inhibitor alters traffic of EGFR and induces a novel form of cetuximab resistance. 2009 , 15, 6570-81	30
1688	Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. 2009 , 27, 5620-6	76
1687	Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. 2009 , 1, 41-8	158
1686	Combined integrin phosphoproteomic analyses and small interfering RNA--based functional screening identify key regulators for cancer cell adhesion and migration. 2009 , 69, 3713-20	80
1685	Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival. 2009 , 69, 2244-51	61
1684	TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. 2009 , 100, 1330-5	75
1683	Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. 2009 , 69, 6889-98	120
1682	Mechanisms of tumor resistance to EGFR-targeted therapies. 2009 , 13, 339-62	66
1681	EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. 2009 , 62, 970-7	94
1680	Pharmacology and Therapeutics of Airway Disease. 2009 ,	
1679	Positron emission tomography (PET) imaging with [¹¹ C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. 2009 , 69, 873-8	135
1678	HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. 2009 , 15, 4829-37	123
1677	Targeting epidermal growth factor receptor 1 signaling in human thyroid-stimulating hormone-independent thyroid carcinoma FRO cells results in a more chemosensitive and less angiogenic phenotype. 2009 , 19, 629-37	9
1676	Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. 2009 , 15, 1585-92	80
1675	The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. 2009 , 8, 618-26	142
1674	Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies. 2009 , 1, 590-9	5
1673	Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck. 2009 , 6, 132-3	9
1672	Safety of multi-targeted kinase inhibitors as monotherapy treatment of cancer: a systematic review of the literature. 2009 , 4, 143-54	9

1671	Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies. 2009 , 16, 3797-804	22
1670	New Agents [Manifold Consequences: The Management of Lung and Colorectal Cancer is Changing. 2009 , 5, 1-19	
1669	Combination of EGFR signalling pathway inhibitors and prevention of resistance. 2009 , 8, 531-2	
1668	K-RAS mutation in the screening, prognosis and treatment of cancer. 2009 , 3, 757-69	31
1667	EGF receptor as a drug target in arterial hypertension. 2009 , 9, 526-38	12
1666	Apoptosis and apoptosis-based therapy in lung cancer. 2009 , 9, 952-7	9
1665	A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. 2009 , 15, 5895-901	91
1664	First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype. 2009 , 9, 425-35	23
1663	The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway. 2009 , 77 Suppl 1, 57-68	38
1662	Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. 2009 , 20, 1596-1603	166
1661	EGFR-targeted therapies in lung cancer: predictors of response and toxicity. 2009 , 10, 59-68	54
1660	The role of EGFR inhibition in the treatment of non-small cell lung cancer. 2009 , 14, 1116-30	44
1659	Chemokines in tumor-associated angiogenesis. 2009 , 390, 1213-23	56
1658	EGF-receptor regulation of matrix metalloproteinases in epithelial ovarian carcinoma. 2009 , 5, 323-38	27
1657	Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. 2009 , 8, 1547-56	25
1656	Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. 2009 , 16, 17-44	296
1655	Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. 2009 , 20, 213-26	31
1654	Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor. 2009 , 69, 6179-83	72

1653	Stage IIIA N2 non-small-cell lung cancer: current controversies in combined-modality therapy. 2009 , 36, 431-2	2
1652	A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth. 2009 , 9, 198	47
1651	Pharmacokinetics of erlotinib for the treatment of high-grade glioma in a pediatric patient with cystic fibrosis: case report and review of the literature. 2009 , 29, 858-66	10
1650	Global upregulation of gene expression associated with renal dysfunction in DOCA-salt-induced hypertensive rats occurs via signaling cascades involving epidermal growth factor receptor: a microarray analysis. 2009 , 51, 101-9	23
1649	ErbB receptors and cell polarity: new pathways and paradigms for understanding cell migration and invasion. 2009 , 315, 707-16	44
1648	Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. 2009 , 78, 460-8	61
1647	Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. 2009 , 625, 6-22	18
1646	Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma. 2009 , 124, 2744-9	39
1645	Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. 2009 , 125, 2393-9	87
1644	Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. 2009 , 135, 1429-35	121
1643	Antitumor effect of RNA interference on non-small-cell lung cancer in vivo. 2009 , 8, 463-466	
1642	Haut- und Schleimhauttoxizität neuer Substanzen. 2009 , 15, 163-168	5
1641	Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer. 2009 , 11, 737-747	7
1640	EGFR FISH analysis in colorectal cancer as a tool in selecting patients for antiEGFR monoclonal antibodies therapy. 2009 , 3, 187-193	1
1639	Epidermal growth factor receptor pathway as therapeutic development in head and neck cancers: present and future. 2009 , 3, 137-148	1
1638	Tyrosinkinaseinhibitoren beim nichtkleinzelligen Lungenkarzinom. 2009 , 2, 80-85	
1637	Hautveränderungen durch Targeted therapies 2009 , 4, 42-49	
1636	Cancer colorectal métastatique et thérapies ciblées. 2009 , 3, 230-238	

1635	[Skin changes as a result of targeted therapies in oncology patients: cutaneous side effects of targeted therapies in oncology patients]. 2009 , 60, 433-40	1
1634	[EGFR mutation analysis in non-small-cell lung cancer : Experience from routine diagnostics]. 2009 , 30, 384-92	22
1633	Characterization of membranous and cytoplasmic EGFR expression in human normal renal cortex and renal cell carcinoma. 2009 , 16, 82	29
1632	HER2 overexpression correlates with survival after curative resection of pancreatic cancer. 2009 , 100, 1243-7	89
1631	Radiosensitizing effects of gefitinib at different administration times in vitro. 2009 , 100, 1520-5	34
1630	Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. 2009 , 161, 515-21	94
1629	Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. 2009 , 158, 1-9	221
1628	Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. 2009 , 23, 477-85	216
1627	Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. 2009 , 6, 352-66	178
1626	Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. 2009 , 28 Suppl 1, S14-23	163
1625	Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. 2009 , 28 Suppl 1, S24-31	636
1624	Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines. 2009 , 28, 4249-60	47
1623	Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. 2009 , 100, 1087-94	103
1622	Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. 2009 , 205, 858-62	223
1621	Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. 2009 , 45, 1117-1128	71
1620	Targeted therapies in the treatment of advanced/metastatic NSCLC. 2009 , 45, 2473-87	57
1619	EGFR-Nrf2 pathway plays a role in cancer cell's chemoresistance. 2009 , 2, 261-263	4
1618	Dissociation of EphB2 signaling pathways mediating progenitor cell proliferation and tumor suppression. 2009 , 139, 679-92	134

1617	EGF promotes invasion by PANC-1 cells through Rac1/ROS-dependent secretion and activation of MMP-2. 2009 , 379, 445-50	84
1616	Review of the gastrointestinal tract: from macro to micro. 2009 , 25, 3-14	17
1615	The juxtamembrane region of the EGF receptor functions as an activation domain. 2009 , 34, 641-51	229
1614	Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. 2009 , 6, 519-27	341
1613	An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy. 2009 , 64, 199-206	19
1612	Association of an EGFR intron 1 SNP with never-smoking female lung adenocarcinoma patients. 2009 , 64, 251-6	28
1611	Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis. 2009 , 21, 1023-8	41
1610	MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. 2009 , 8, 102	272
1609	Immune therapy for cancer. 2009 , 27, 83-117	476
1608	A pan-HER approach for cancer therapy: background, current status and future development. 2009 , 9, 97-110	37
1607	The epidermal growth factor receptor: a link between inflammation and liver cancer. 2009 , 234, 713-25	91
1606	The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro. 2009 , 28, 123	15
1605	The biological effect of 125I seed continuous low dose rate irradiation in CL187 cells. 2009 , 28, 12	40
1604	Systems pharmacology and genome medicine: a future perspective. 2009 , 1, 11	63
1603	A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. 2009 , 11, 543-52	92
1602	Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. 2009 , 9, 217-21	85
1601	Selenium decreases thyroid cancer cell growth by increasing expression of GADD153 and GADD34. 2010 , 62, 66-73	28
1600	Subcutaneous administration of epidermal growth factor: a true treatment option in case of postoperative liver failure?. 2009 , 7, 200-5	3

1599	Anticancer strategies involving the vasculature. 2009 , 6, 395-404	215
1598	Role of molecular markers and gene profiling in head and neck cancers. 2009 , 21, 206-11	31
1597	KRAS mutation testing in colorectal cancer. 2009 , 16, 196-203	82
1596	Optimizing systemic therapy in squamous cell carcinoma of the head and neck with a focus on targeted agents. 2009 , 21, 232-7	9
1595	Regulation and signaling of human bombesin receptors and their biological effects. 2009 , 16, 66-71	54
1594	Time to target evaluation criteria of targeted therapies. 2009 , 30, 487-9	1
1593	Gastrointestinal regulatory peptides. 2009 , 16, 45-6	1
1592	State of the art management in spine oncology: a worldwide perspective on its evolution, current state, and future. 2009 , 34, S7-20	27
1591	Determination of EGFR status in gliomas: usefulness of immunohistochemistry and fluorescent in situ hybridization. 2009 , 17, 220-6	16
1590	Differentiation therapy of leukemia: 3 decades of development. 2009 , 113, 3655-65	247
1589	EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. 2009 , 4, 318-25	45
1588	Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma. 2009 , 9, 931-7	28
1587	Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?. 2009 , 20, 856-66	43
1586	EGFR Antagonists in Cancer Treatment. 2009 , 2009, 177-179	3
1585	Anti-EGFR therapy in colorectal cancer: how to choose the right patient. 2009 , 10, 1033-40	10
1584	Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. 2009 , 20, 851-5	133
1583	Molecular targeted therapy of biliary tract cancer--results of the first clinical studies. 2010 , 11, 834-50	29
1582	Interstitial Lung Disease in Japanese Patients with Lung Cancer: A Cohort and Nested Case-Control Study. 2010 , 2010, 143-145	

1581	KRAS Mutation Analysis Prior to EGFR-Directed Therapy for Metastatic Colorectal Cancer: A Review and Cost Analysis. 2010 , 6, 256-261	3
1580	Validation of a Model to Predict Perioperative Mortality from Lung Cancer Resection in the Elderly. 2010 , 2010, 145-147	
1579	Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?. 2010 , 16, 23-32	106
1578	ErbB targeted drugs and angiogenesis. 2010 , 8, 421-31	9
1577	Thymic tumors: relevant molecular data in the clinic. 2010 , 5, S291-5	47
1576	Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. 2010 , 5, 1382-90	110
1575	Combination Effect of Cetuximab with Radiation in Colorectal Cancer Cells. 2010 , 96, 713-720	11
1574	KRAS mutation testing in human cancers: The pathologist's role in the era of personalized medicine. 2010 , 17, 23-32	72
1573	Is cytology reliable for epidermal growth factor receptor gene evaluation in non-small cell lung cancer?. 2010 , 5, 551-3	7
1572	Hexa-, hepta- and nonaprenylhydroquinones isolated from marine sponges <i>Sarcotragus muscarum</i> and <i>Ircinia fasciculata</i> inhibit NF- κ B signalling in H4IIE cells. 2010 , 61, 919-924	
1571	KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. 2010 , 17, 1429-34	96
1570	Chronotherapy and the molecular clock: Clinical implications in oncology. 2010 , 62, 979-1001	118
1569	Lung adenocarcinoma: lessons in translation from bench to bedside. 2010 , 77, 597-605	30
1568	[Pathological diagnosis for individualized therapy of colorectal cancer]. 2010 , 31, 16-21	2
1567	[Therapy with epidermal growth factor receptor inhibitors. Clinical spectrum of cutaneous adverse effects]. 2010 , 61, 654-61	9
1566	Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma. 2010 , 457, 483-95	39
1565	Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. 2010 , 15, 242-55	28
1564	Systemtherapie des Ösophaguskarzinoms und Stellenwert zielgerichteter Substanzen. 2010 , 16, 515-520	

1563	EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. 2010 , 5, 245-55	50
1562	KRAS testing and its importance in colorectal cancer. 2010 , 12, 160-7	9
1561	Molecular testing in lung cancer: the time is now. 2010 , 12, 335-48	18
1560	Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. 2010 , 29, 37-48	75
1559	Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET. 2010 , 12, 616-25	16
1558	Downregulation of EGFR by a novel multivalent nanobody-liposome platform. 2010 , 145, 165-75	99
1557	Tapered dose versus constant drug exposure to anti-EGFR drugs on head-and-neck cancer xenografts. A comparison between cetuximab and gefitinib. 2010 , 46, 172-7	2
1556	Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. 2010 , 10, 189	58
1555	Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report. 2010 , 10, 570	10
1554	Therapeutic modulation of k-ras signaling in colorectal cancer. 2010 , 15, 502-16	27
1553	Methods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling. 2010 , 80, 739-47	15
1552	Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines. 2010 , 80, 179-87	27
1551	Oncologist's/haematologist's view on the roles of pathologists for molecular targeted cancer therapy. 2010 , 14, 805-17	2
1550	Individualized medicine 2010. 2010 , 14, 2257-63	1
1549	Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. 2010 , 126, 589-98	156
1548	KRAS mutation analysis on cytological specimens of metastatic colo-rectal cancer. 2010 , 38, 869-73	19
1547	A new A431/cell membrane chromatography and online high performance liquid chromatography/mass spectrometry method for screening epidermal growth factor receptor antagonists from Radix sophorae flavescentis. 2010 , 1217, 5246-52	91
1546	Optimizing the management of metastatic colorectal cancer. 2010 , 75, 15-26	3

1545	Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells. 2010 , 101, 1080-8	38
1544	TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. 2010 , 29, 1588-97	45
1543	Nuclear trafficking of the epidermal growth factor receptor family membrane proteins. 2010 , 29, 3997-4006	166
1542	Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. 2010 , 29, 2616-27	66
1541	PTEN status in advanced colorectal cancer treated with cetuximab. 2010 , 102, 162-4	68
1540	Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). 2010 , 102, 500-5	150
1539	Dual inhibition of EGFR and mTOR pathways in small cell lung cancer. 2010 , 103, 622-8	49
1538	Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands. 2010 , 103, 510-6	40
1537	Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. 2010 , 103, 1542-7	137
1536	Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. 2010 , 103, 1765-72	61
1535	Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. 2010 , 28, 585-93	191
1534	Targeting the cancer kinome through polypharmacology. 2010 , 10, 130-7	542
1533	The current status of targeted therapy for non-small cell lung cancer. 2010 , 40, 611-8	17
1532	Management of patients with advanced non-small cell lung cancer: role of gefitinib. 2010 , 4, 83-90	1
1531	Receptor-based virtual screening of EGFR kinase inhibitors from the NCI diversity database. 2010 , 15, 4041-54	28
1530	Phospholipase D2 Enhances Epidermal Growth Factor-Induced Akt Activation in EL4 Lymphoma Cells. 2010 , 3, 2045-2058	3
1529	Fascin expression in colorectal carcinomas. 2010 , 65, 157-64	18
1528	Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer. 2010 , 2, 143-56	19

1527	Targeting the EGF receptor for ovarian cancer therapy. 2010 , 2010, 414676	52
1526	Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs. 2010 , 8, 809-20	59
1525	Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. 2010 , 31, 577-86	129
1524	New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. 2010 , 16, 3811-8	38
1523	Mechanisms of Oncogenesis. 2010 ,	3
1522	AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. 2010 , 16, 1159-69	91
1521	The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer. 2010 , 19, 186-96	28
1520	Re: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. 2010 , 102, 573; author reply 573-5	1
1519	Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. 2010 , 16, 291-303	117
1518	Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. 2010 , 17, 7-16	88
1517	Intestinal permeability, vitamin A absorption and serum alpha-tocopherol during therapy with gefitinib. 2010 , 70, 180-7	4
1516	Ovarian cancer: individualized and personalized care. 2010 , 5, 409-419	2
1515	A study of HER2 gene amplification and protein expression in gastric cancer. 2010 , 63, 839-42	82
1514	Palliative treatment of unresectable metastatic colorectal cancer. 2010 , 11, 63-77	16
1513	Therapeutic targeting of EGFR in malignant gliomas. 2010 , 14, 303-16	20
1512	Quantifying EGFR alterations in the lung cancer genome with nanofluidic digital PCR arrays. 2010 , 56, 623-32	82
1511	ZD6474 coerces breast cancer for an apoptotic journey. 2010 , 9, 604-6	
1510	New and potential clinical applications of KRAS as a cancer biomarker. 2010 , 4, 383-95	5

1509	Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. 2010 , 184, 512-20	183
1508	Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. 2010 , 16, 4990-5001	70
1507	The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. 2011 , 18, 1-11	52
1506	Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. 2010 , 21 Suppl 6, vi1-10	35
1505	Genome-wide association study for colorectal cancer identifies risk polymorphisms in German familial cases and implicates MAPK signalling pathways in disease susceptibility. 2010 , 31, 1612-9	48
1504	Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. 2010 , 15, 1320-8	92
1503	Novel insights into the molecular origins and treatment of lung cancer. 2010 , 9, 4098-105	15
1502	Cetuximab concomitant with second-line radiation therapy in patients with locally advanced recurrent squamous cell head and neck cancer. 2010 , 3, 480-8	1
1501	Clinicopathological significance of prolactin receptor expression in colorectal carcinoma and corresponding metastases. 2010 , 23, 961-71	15
1500	Integrin signaling and lung cancer. 2010 , 4, 124-9	40
1499	Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study. 2010 , 79, 415-22	16
1498	[Palliative chemotherapy for colorectal cancer--current state, significance, trends]. 2010 , 135, 535-40	1
1497	EGFR Mutation Testing in Non-Small Cell Lung Cancer. 2010 , 6, 310-321	2
1496	Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy. 2010 , 31, 1181-8	39
1495	Strategies for overcoming inherent and acquired resistance to EGFR inhibitors by targeting downstream effectors in the RAS/PI3K pathway. 2010 , 10, 824-33	22
1494	Favorable response to gefitinib treatment of lung adenocarcinoma with coexisting germline and somatic epidermal growth factor receptor mutations. 2010 , 28, e701-3	8
1493	Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer. 2010 , 11, 2363-89	18
1492	miRNAs as biomarkers for management of patients with colorectal cancer. 2010 , 4, 761-70	17

1491	Roles of autophagy in cetuximab-mediated cancer therapy against EGFR. 2010 , 6, 1066-77	79
1490	The epidermal growth factor variant III peptide vaccine for treatment of malignant gliomas. 2010 , 21, 87-93	24
1489	Lung injury and cancer: Mechanistic insights into ceramide and EGFR signaling under cigarette smoke. 2010 , 43, 259-68	62
1488	Cutaneous consequences of inhibiting EGF receptor signaling in vivo: normal hair follicle development, but retarded hair cycle induction and inhibition of adipocyte growth in Egfr(Wa5) mice. 2010 , 57, 155-61	18
1487	Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. 2010 , 67, 86-92	19
1486	Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers. 2010 , 67, 355-60	59
1485	Comparison of four antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in non-small cell lung cancer. 2010 , 69, 46-50	15
1484	New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. 2010 , 69, 1-12	52
1483	Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency. 2010 , 53, 7316-26	93
1482	Molecular aspects of thyroid hormone actions. 2010 , 31, 139-70	904
1481	Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. 2010 , 9, 297-304	17
1480	Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo. 2010 , 9, 139	60
1479	In vivo molecular imaging of colorectal cancer with confocal endomicroscopy by targeting epidermal growth factor receptor. 2010 , 138, 435-46	176
1478	Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer. 2010 , 138, 2163-76	74
1477	Targeted therapies in cancer. 2010 , 24, 77-88	29
1476	Energy balance, host-related factors, and cancer progression. 2010 , 28, 4058-65	187
1475	Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. 2010 , 28, 1254-61	582
1474	The molecular therapy of colorectal cancer. 2010 , 31, 171-8	42

1473	Development of cetuximab-resistant human nasopharyngeal carcinoma cell lines and mechanisms of drug resistance. 2010 , 64, 550-8	12
1472	Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis. 2010 , 46, 1613-9	37
1471	Molecular networks in respiratory epithelium carcinomas. 2010 , 295, 1-6	
1470	Epidermal growth factor-induced epithelial-mesenchymal transition in human esophageal carcinoma cells--a model for the study of metastasis. 2010 , 296, 88-95	25
1469	Cetuximab-conjugated magneto-fluorescent silica nanoparticles for in vivo colon cancer targeting and imaging. 2010 , 299, 63-71	78
1468	Apoptosis assays for quantifying the bioactivity of anticancer drug products. 2010 , 13, 172-9	36
1467	Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC). 2010 , 46, 1703-11	55
1466	Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. 2010 , 46, 1829-34	67
1465	Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. 2010 , 140, 268-79	270
1464	Toxic epidermal necrolysis caused by cetuximab plus minocycline in head and neck cancer. 2010 , 31, 288-90	14
1463	Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. 2010 , 14, 337-49	32
1462	Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. 2010 , 36 Suppl 3, S11-5	68
1461	Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. 2010 , 36 Suppl 3, S21-9	97
1460	Asymmetric distribution of epidermal growth factor receptor directs the fate of normal and cancer keratinocytes in vitro. 2010 , 19, 209-20	16
1459	[Recent developments of pharmacogenomics in the treatment of colorectal cancers]. 2010 , 68, 233-53	2
1458	RON receptor tyrosine kinase as a target for delivery of chemodrugs by antibody directed pathway for cancer cell cytotoxicity. 2010 , 7, 386-97	33
1457	Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. 2010 , 28, 4425-33	86
1456	Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification. 2010 , 53, 4980-8	56

1455	Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer. 2010 , 29, 125	12
1454	Ovarian Cancer. 2010 ,	1
1453	New platform for controlled and sustained delivery of the EGF receptor tyrosine kinase inhibitor AG1478 using poly(lactic-co-glycolic acid) microspheres. 2010 , 27, 263-71	4
1452	Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. 2010 , 14, 375-84	36
1451	Cetuximab therapy for head and neck squamous cell carcinoma: a systematic review of the data. 2011 , 144, 676-84	34
1450	Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. 2011 , 17, 6531-41	42
1449	Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. 2011 , 17, 4901-14	143
1448	Regulation of EGFR protein stability by the HECT-type ubiquitin ligase SMURF2. 2011 , 13, 570-8	36
1447	Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity. 2011 , 13, 461-71	56
1446	Targeted therapies for thymic malignancies. 2011 , 21, 115-23, viii	8
1445	[A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC)]. 2011 , 28, 51-7	6
1444	Biomedical applications of tetrazine cycloadditions. 2011 , 44, 816-27	375
1443	Therapeutic approaches to target cancer stem cells. 2011 , 3, 3331-52	22
1442	Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors. 2011 , 71, 283-90	24
1441	Bronchoscopic microsampling is a useful complementary diagnostic tool for detecting lung cancer. 2011 , 72, 32-8	17
1440	[New antitarget antineoplastic drugs. Clinical indications in the treatment of cancer]. 2011 , 137, 370-6	1
1439	HER2 signaling and resistance to the anti-EGFR monoclonal antibody cetuximab: a further step toward personalized medicine for patients with colorectal cancer. 2011 , 1, 472-4	27
1438	Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis. 2011 , 10, 63-9	35

1437	Comparison of KRAS mutation tests in colorectal cancer patients. 2011 , 15, 831-4	9
1436	Survival and death signals can predict tumor response to therapy after oncogene inactivation. 2011 , 3, 103ra99	34
1435	The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. 2011 , 7, 519-41	35
1434	Guidelines for Molecular Analysis in Archive Tissues. 2011 ,	14
1433	Development of molecular biomarkers in individualized treatment of colorectal cancer. 2011 , 10, 279-89	22
1432	Development of novel targeted agents in the treatment of metastatic colorectal cancer. 2011 , 10, 266-78	5
1431	Use of molecular markers for predicting therapy response in cancer patients. 2011 , 37, 151-9	82
1430	Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?. 2011 , 37, 533-42	28
1429	Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib. 2011 , 306, 85-91	10
1428	Resveratrol inhibits the epidermal growth factor-induced epithelial mesenchymal transition in MCF-7 cells. 2011 , 310, 1-8	78
1427	Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways. 2011 , 47, 1946-54	43
1426	CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA) _n polymorphism. 2011 , 47, 1962-70	27
1425	A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). 2011 , 47, 2331-40	93
1424	A receptor tyrosine kinase inhibitor, Tyrphostin A9 induces cancer cell death through Drp1 dependent mitochondria fragmentation. 2011 , 408, 465-70	20
1423	Novel irreversible EGFR tyrosine kinase inhibitor 324674 sensitizes human colon carcinoma HT29 and SW480 cells to apoptosis by blocking the EGFR pathway. 2011 , 411, 751-6	6
1422	Targeted imaging of colorectal dysplasia in living mice with fluorescence microendoscopy. 2011 , 2, 981-6	10
1421	Novel oncologic drugs: what they do and how they affect images. 2011 , 31, 2059-91	62
1420	Emerging treatments for choroidal metastases. 2011 , 56, 511-21	41

1419	KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. 2011 , 12, 594-603	453
1418	Promising therapies, prohibitive costs: a qualitative assessment of the effects of the Medicare Part D doughnut hole on access to costly cancer medications. 2011 , 8, 111-117	2
1417	Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer. 2011 , 25, 355-7	20
1416	Targeted Therapy in Patients With Non-small Cell Lung Cancer Previously Treated With Chemotherapy. 2011 , 47, 520	4
1415	Isolation and characterization of erlotinib-resistant human non-small cell lung cancer A549 cells. 2011 , 2, 91-94	10
1414	Immunohistochemical expression of the epidermal growth factor receptor (EGFR) in colorectal carcinoma: relation with clinicopathological parameters. 2011 , 31, 225-232	3
1413	Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials. 2011 , 2, 449-455	3
1412	A pharmacological primer of biased agonism. 2011 , 11, 92-8	18
1411	Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 2011 , 6, e28841	34
1410	ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. 2011 , 6, e17979	49
1409	Inhibition of cell proliferation by an anti-EGFR aptamer. 2011 , 6, e20299	132
1408	Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. 2011 , 54, 1170-8	63
1407	Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer. 2011 , 39, 271-8	9
1406	Molecular targeting of breast cancer: imaging and therapy. 2011 , 12, 528-38	3
1405	Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab. 2011 , 11, 732-9	6
1404	KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib. 2011 , 25, 1021-9	15
1403	Comprehensive analysis of epidermal growth factor receptor gene status in lung adenocarcinoma. 2011 , 6, 1016-21	17
1402	Bag3 promotes resistance to apoptosis through Bcl-2 family members in non-small cell lung cancer. 2012 , 27, 109-13	22

1401	Mechanism of EGFR-related cancer drug resistance. 2011 , 22, 963-70	7
1400	How pharmacogenomics of biological response modifiers will influence clinical response and toxicity in dermatology. 2011 , 50, 114-8	
1399	Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. 2011 , 50, 129-46	45
1398	Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII). 2011 , 102, 1761-8	22
1397	Gefitinib-induced epidermal growth factor receptor-independent keratinocyte apoptosis is mediated by the JNK activation pathway. 2011 , 164, 38-46	14
1396	Epidermal growth factor receptor inhibitors in the treatment of nonmelanoma skin cancers. 2011 , 37, 1199-209	10
1395	Adaptive informatics for multifactorial and high-content biological data. 2011 , 8, 487-93	56
1394	Cell-free nucleic acids as biomarkers in cancer patients. 2011 , 11, 426-37	1939
1393	A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. 2011 , 104, 427-32	38
1392	Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. 2011 , 104, 1440-51	87
1391	Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway. 2011 , 251, 130-6	47
1390	EGFR-targeted therapy. 2011 , 317, 2765-71	83
1389	Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations. 2011 , 6, 118	24
1388	Biomarkers, prediction, and prognosis in non-small-cell lung cancer: a platform for personalized treatment. 2011 , 12, 360-8	22
1387	Integration of EGFR inhibitors and conventional chemotherapy in the treatment of non-small-cell lung cancer. 2011 , 12, 350-9	14
1386	A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. 2011 , 20, 472-86	280
1385	Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors. 2011 , 222, 144-7	44
1384	EGFR mutations and lung cancer. 2011 , 6, 49-69	387

1383	Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation. 2011 , 71, 5535-45	66
1382	Predictive biomarkers: a paradigm shift towards personalized cancer medicine. 2011 , 8, 587-96	209
1381	Rosacea: The cytokine and chemokine network. 2011 , 15, 40-7	88
1380	Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer. 2011 , 37, 183-93	30
1379	Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial. 2011 , 126, 463-70	54
1378	IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR. 2011 , 130, 465-75	41
1377	Value of post-operative reassessment of estrogen receptor expression following neoadjuvant chemotherapy with or without gefitinib for estrogen receptor negative breast cancer. 2011 , 128, 165-70	2
1376	A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). 2011 , 67, 465-74	28
1375	Cetuximab enhances the activities of irinotecan on gastric cancer cell lines through downregulating the EGFR pathway upregulated by irinotecan. 2011 , 68, 871-8	20
1374	Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers. 2011 , 67, 729-39	23
1373	Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review. 2011 , 28, 79-82	16
1372	Individualisierte Medizin 2011. 2011 , 6, 106-111	1
1371	Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials. 2011 , 13, 21-7	32
1370	Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma. 2011 , 9, 126	49
1369	Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib. 2011 , 4, 5	22
1368	Stromal features are predictive of disease mortality in oral cancer patients. 2011 , 223, 470-81	216
1367	MicroRNAs in colorectal cancer metastasis. 2011 , 224, 438-47	103
1366	Establishment of A431 cell membrane chromatography-RPLC method for screening target components from Radix Caulophylli. 2011 , 34, 508-13	25

1365	Epidermal growth factor receptor mutations in patients with oral cavity cancer in a betel nut chewing-prevalent area. 2011 , 33, 1758-64	17
1364	Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. 2011 , 117, 3173-81	45
1363	EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. 2011 , 119, 80-91	95
1362	KRAS testing on colo-rectal carcinoma cytological imprints. 2011 , 39, 274-7	9
1361	Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review. 2011 , 39, 703-10	46
1360	Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. 2011 , 128, 1981-8	41
1359	Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. 2011 , 79, 224-50	30
1358	Airway epithelial epidermal growth factor receptor mediates hogbarn dust-induced cytokine release but not Ca ²⁺ response. 2011 , 45, 882-8	10
1357	Docking and molecular dynamics study on the inhibitory activity of novel inhibitors on epidermal growth factor receptor (EGFR). 2011 , 7, 24-31	61
1356	Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies. 2011 , 11, 1005-24	19
1355	Bone metastatic disease: taking aim at new therapeutic targets. 2011 , 18, 3093-115	19
1354	Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation. 2011 , 10, 794-804	53
1353	Changing pathology with changing drugs: tumors of the gastrointestinal tract. 2011 , 78, 76-89	13
1352	Epidermal growth factor receptor 1 expression is upregulated in undifferentiated thyroid carcinomas in humans. 2011 , 21, 1227-34	25
1351	Colorectal cancer molecular biology moves into clinical practice. 2011 , 60, 116-29	235
1350	Arsenic disulfide synergizes with the phosphoinositide 3-kinase inhibitor PI-103 to eradicate acute myeloid leukemia stem cells by inducing differentiation. 2011 , 32, 1550-8	24
1349	p53 modulates acquired resistance to EGFR inhibitors and radiation. 2011 , 71, 7071-9	90
1348	Clinical significance of miR-146a in gastric cancer cases. 2011 , 17, 4277-84	174

1347	Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. 2011 , 3, 113-25	77
1346	Gastrointestinal and liver diseases: genetic and epigenetic markers. 2011 , 60, 1630-4	2
1345	EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer. 2011 , 22, 545-552	55
1344	[Tyrosine kinase inhibitors]. 2011 , 98, 1321-34	3
1343	Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma. 2011 , 17, 5901-12	32
1342	Erythema Nodosum-like Lesions in a Renal Transplant Recipient Diagnosis. 2011 , 147, 735	
1341	Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects. 2011 , 16, 1006-20	12
1340	Papulopustular Eruptions in a 32-Year-Old Woman After Lung Cancer Treatment Diagnosis. 2011 , 147, 735	
1339	Multiple Café-au Lait Macules and Crowe Sign Diagnosis. 2011 , 147, 735	
1338	Combining EGF receptor inhibitors with chemotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. 2011 , 8, 9-14	1
1337	Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. 2011 , 186, 3770-8	52
1336	Erythematous Shiny Plaque Over the Glans Penis Diagnosis. 2011 , 147, 735	2
1335	Adaptive elastic-net sparse principal component analysis for pathway association testing. 2011 , 10,	6
1334	Non-small cell lung cancer in never-smokers: a new disease entity?. 2011 , 34, 202-7	2
1333	Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. 2011 , 29, 289-302	30
1332	Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members. 2011 , 39, 483-91	20
1331	Curing patients with liver metastases from colorectal cancer. 2011 , 49, 42-5; quiz i-ii	1
1330	Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody. 2011 , 187, 4954-66	70

1329	Engineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes. 2011 , 286, 27729-40	19
1328	Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors. 2011 , 105, 382-92	45
1327	PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer. 2011 , 105, 1850-5	54
1326	Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. 2011 , 105, 1554-62	54
1325	MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents. 2011 , 71, 4494-505	60
1324	KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. 2011 , 17, 6338-46	54
1323	The role of epidermal growth factor receptor mutations and epidermal growth factor receptor-tyrosine kinase inhibitors in the treatment of lung cancer. 2011 , 3, 2667-78	5
1322	Epidermal growth factor receptor in pancreatic cancer. 2011 , 3, 1513-26	77
1321	EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects. 2011 , 3, 2014-31	23
1320	Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy. 2011 , 10, 127-37	20
1319	General aspects of colorectal cancer. 2012 , 2012, 139268	32
1318	Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective. 2012 , 65, 940-4	24
1317	Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. 2012 , 2, 450-7	44
1316	EGFR and KRAS mutations detection on lung cancer liquid-based cytology: a pilot study. 2012 , 65, 87-91	60
1315	Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial. 2012 , 23, 1005-9	11
1314	Crossing paths in Human Renal Cell Carcinoma (hRCC). 2012 , 13, 12710-33	4
1313	Personalized targeted therapy for lung cancer. 2012 , 13, 11471-96	45
1312	Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788. 2012 , 18, 6364-72	12

1311	Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. 2012 , 18, 4986-96	120
1310	The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration. 2012 , 287, 9792-9803	29
1309	EGFR gene copy number increase in vulvar carcinomas is linked with poor clinical outcome. 2012 , 65, 133-9	24
1308	Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation. 2012 , 26, 73-80	11
1307	Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR. 2012 , 18, 3470-7	46
1306	Molecular and clinical analysis of predictive biomarkers in non-small-cell lung cancer. 2012 , 19, 3689-700	10
1305	Changing the receptor specificity of anthrax toxin. 2012 , 3,	42
1304	Personalized therapy in endometrial cancer: challenges and opportunities. 2012 , 13, 1-13	52
1303	Role of EGFR inhibitors in the treatment of central nervous system metastases from non-small cell lung cancer. 2012 , 12, 237-46	11
1302	Assessing tumor heterogeneity and emergence mutations using next-generation sequencing for overcoming cancer drugs resistance. 2012 , 12, 1245-8	8
1301	Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence. 2012 , 2, 317-325	5
1300	Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. 2012 , 106, 719-26	47
1299	Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10. 2012 , 106, 883-8	7
1298	Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. 2012 , 30, 1755-62	416
1297	Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. 2012 , 18, 1051-62	36
1296	Ultrasound-targeted microbubble destruction to deliver siRNA cancer therapy. 2012 , 72, 6191-9	119
1295	Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. 2012 , 109, 16642-7	59
1294	Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector mechanisms of EGFR antibodies. 2012 , 189, 5230-9	49

1293	The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials. 2012 , 23, 1229-1233	13
1292	Research progress on criteria for discontinuation of EGFR inhibitor therapy. 2012 , 5, 263-70	5
1291	New Challenges for Cancer Systems Biomedicine. 2012 ,	6
1290	MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. 2012 , 11, 154-64	100
1289	Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages. 2012 , 287, 25139-50	30
1288	Early FDG/PET scanning as a pharmacodynamic marker of anti-EGFR antibody activity in colorectal cancer. 2012 , 11, 1385-8	14
1287	Combined effects of EGFR and Hedgehog signaling pathway inhibition on the proliferation and apoptosis of pancreatic cancer cells. 2012 , 28, 519-26	13
1286	Tobacco, inflammation, and respiratory tract cancer. 2012 , 18, 3901-38	46
1285	A Japanese post-marketing surveillance of cetuximab (Erbixim) in patients with metastatic colorectal cancer. 2012 , 42, 287-94	36
1284	Recent advances in optical cancer imaging of EGF receptors. 2012 , 19, 4759-66	7
1283	Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation. 2012 , 35, 367-73	24
1282	Resistance to EGF receptor-targeted monoclonal antibodies in the management of advanced colorectal cancer. 2012 , 1, 137-148	1
1281	Pharmacogenetic screening for drug therapy: from single gene markers to decision making in the next generation sequencing era. 2012 , 44, 166-80	17
1280	Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors. 2012 , 7, 40-8	36
1279	<i>Althaea rosea</i> Cavanil and <i>Plantago major</i> L. suppress neoplastic cell transformation through the inhibition of epidermal growth factor receptor kinase. 2012 , 6, 843-7	10
1278	Rapid Visualization of Human Tumor Xenografts through Optical Imaging with a Near-Infrared Fluorescent AntiEpidermal Growth Factor Receptor Nanobody. 2012 , 11, 7290.2011.00025	119
1277	Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma. 2012 , 7, 993-1000	25
1276	Clinical trial design in the age of molecular profiling. 2012 , 823, 19-34	2

1275	EGFR signaling upregulates expression of microsomal prostaglandin E synthase-1 in cancer cells leading to enhanced tumorigenicity. 2012 , 31, 3457-66	23
1274	FOXO3a and Eatenin co-localization: double trouble in colon cancer?. 2012 , 18, 854-6	11
1273	Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. 2012 , 2, 458-71	240
1272	Isolation of human mAbs that directly modulate FMS-related tyrosine kinase 3 signaling. 2012 , 103, 350-9	2
1271	Clinical trials and future potential of targeted therapy for ovarian cancer. 2012 , 17, 430-40	30
1270	IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients. 2012 , 136, 659-71	38
1269	Directed Therapies in Lung Cancer: New Hope?. 2012 , 48, 367-371	1
1268	Directed therapies in lung cancer: new hope?. 2012 , 48, 367-71	5
1267	Non-clinical immuno-toxicological evaluation of HER1 cancer vaccine in non-human primates: a 12-month study. 2012 , 31, 89-95	4
1266	Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. 2012 , 127, 141-6	58
1265	Clinical trials in idiopathic pulmonary fibrosis: where we have been and where we are going. 2012 , 1, 216-223	
1264	Epidermal growth factor receptor (EGFR) gene copy number in colorectal adenoma-carcinoma progression. 2012 , 205, 630-5	8
1263	Mechanisms of action of EGFR inhibitors. 2012 , 6-17	1
1262	EGFR mutation testing in non-small cell lung cancer (NSCLC). 2012 , 5 Suppl 1, S31-4	10
1261	Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. 2012 , 58, 263-8	4
1260	The roles of epidermal growth factor receptor (EGFR) inhibitors in the management of lung cancer. 2012 , 5 Suppl 1, S50-60	16
1259	Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. 2012 , 58, 263-268	
1258	Sequenziamento mediante pyrosequencing: un'analisi rapida e sensibile per la determinazione delle mutazioni di EGFR nel carcinoma polmonare non a piccole cellule. 2012 , 5, 27-35	

1257	Salivary gland carcinomas. 2012 , 16, 267-83	72
1256	Microfluidics separation reveals the stem-cell-like deformability of tumor-initiating cells. 2012 , 109, 18707-12	163
1255	Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies. 2012 , 106, 173-83	52
1254	Current and emerging medical treatments for non-small cell lung cancer: a primer for pulmonologists. 2012 , 106, 473-92	8
1253	Recent applications of multicomponent reactions in medicinal chemistry. 2012 , 3, 1189	330
1252	Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine/methionine mutant. 2012 , 55, 2711-23	69
1251	Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. 2012 , 12, 593-602	70
1250	Hotspot oncomutations: implications for personalized cancer treatment. 2012 , 12, 603-20	12
1249	Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma. 2012 , 57, 592-9	25
1248	EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. 2012 , 43, 921-31	55
1247	Differential macrophage programming in the tumor microenvironment. 2012 , 33, 119-26	616
1246	The major vault protein mediates resistance to epidermal growth factor receptor inhibition in human hepatoma cells. 2012 , 319, 164-172	22
1245	Gambogic acid induces G1 arrest via GSK3 β -dependent cyclin D1 degradation and triggers autophagy in lung cancer cells. 2012 , 322, 185-94	58
1244	First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. 2012 , 30, 3002-11	193
1243	Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients. 2012 , 17, 4	14
1242	Pathways and targets in hepatocellular carcinoma. 2012 , 12, 1347-57	51
1241	Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. 2012 , 7, e30339	99
1240	EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?. 2012 , 107, 1864-8	50

1239	Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations. 2012 , 55, 10685-99	37
1238	RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer. 2012 , 39, 677-84	37
1237	A role for the epidermal growth factor receptor signaling in development of intestinal serrated polyps in mice and humans. 2012 , 143, 730-740	28
1236	5-Fluorocytosine combined with Fcy-hEGF fusion protein targets EGFR-expressing cancer cells. 2012 , 428, 292-7	3
1235	Absence of evidence for epidermal growth factor receptor and human homolog of the Kirsten rat sarcoma-2 virus oncogene mutations in breast cancer. 2012 , 36, 341-6	8
1234	The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. 2012 , 36, 490-6	61
1233	Epidermal growth factor receptor (EGFR) in salivary gland carcinomas: potentials as therapeutic target. 2012 , 48, 991-996	27
1232	Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma. 2012 , 48, 1202-7	17
1231	[Cell signalling and cancer: characterisation of therapeutic targets]. 2012 , 60, 217-22	1
1230	Management of squamous cell carcinoma of the head and neck in the elderly: Review and recommendations. 2012 , 3, 265-272	1
1229	HER family receptor and ligand status in thymic carcinoma. 2012 , 77, 515-21	26
1228	Molecular aspects of thymic carcinoma. 2012 , 78, 127-32	20
1227	Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients. 2012 , 72 Suppl 1, 11-9	14
1226	Cetuximab in non-small-cell lung cancer. 2012 , 12, 163-75	16
1225	Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBP β -dependent suppression of EGFR expression. 2012 , 14, 190-205	15
1224	Design, synthesis and biological evaluation of new molecules inhibiting epidermal growth factor receptor threonine790-methionine790 mutant. 2012 , 3, 1155	16
1223	New biologic agents for the treatment of gynecologic cancers. 2012 , 26, 133-56	6
1222	Cancer Chemotherapy in Clinical Practice. 2012 ,	4

1221	Sex and Gender Differences in Pharmacology. 2012,	26
1220	Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer. 2012, 31, 77	18
1219	Mechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells. 2012, 31, 72	20
1218	Differential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues. 2012, 31, 36	28
1217	Development and validation of a spectrofluorimetric method for the determination of erlotinib in spiked human plasma. 2012, 22, 1425-9	14
1216	PTRF/cavin-1 and MIF proteins are identified as non-small cell lung cancer biomarkers by label-free proteomics. 2012, 7, e33752	55
1215	Activation of EGFR/ERBB2 via pathways involving ERK1/2, P38 MAPK, AKT and FOXO enhances recovery of diabetic hearts from ischemia-reperfusion injury. 2012, 7, e39066	55
1214	Combined EGFR and VEGFR versus single EGFR signaling pathways inhibition therapy for NSCLC: a systematic review and meta-analysis. 2012, 7, e40178	6
1213	Gefitinib analogue V1801 induces apoptosis of T790M EGFR-harboring lung cancer cells by up-regulation of the BH-3 only protein Noxa. 2012, 7, e48748	12
1212	True 3q chromosomal amplification in squamous cell lung carcinoma by FISH and aCGH molecular analysis: impact on targeted drugs. 2012, 7, e49689	10
1211	Thrombin stimulation of inflammatory breast cancer cells leads to aggressiveness via the EGFR-PAR1-Pak1 pathway. 2012, 27, e305-13	16
1210	Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. 2012, 2012, 737981	36
1209	Targeted Nanoparticles for Cancer Therapy. 2012,	10
1208	The Role of Tyrosine Kinases in the Pathogenesis and Treatment of Lung Disease. 2012,	2
1207	Target Therapy for Hepatocellular Carcinoma. 2012, 32, 118	
1206	Bevacizumab in combination with chemotherapy in the first-line treatment of metastatic colorectal carcinoma. 2013, 60, 83-91	3
1205	Cetuximab and biomarkers in non-small-cell lung carcinoma. 2012, 6, 221-31	8
1204	High-expression EGFR/cell membrane chromatography-online-high-performance liquid chromatography/mass spectrometry: rapid screening of EGFR antagonists from Semen Strychni. 2012, 26, 2027-32	22

1203	Molecular pathology of lung cancer: key to personalized medicine. 2012 , 25, 347-69	171
1202	Use and costs of oral anticancer agents in the Netherlands in the period 2000-2008. 2012 , 21, 1036-44	16
1201	Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. 2012 , 72, 2924-30	92
1200	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. 2012 , 486, 532-6	1327
1199	Single domain antibodies: a new concept for epidermal growth factor receptor and EGFRvIII targeting. 2012 , 31, 1015-26	16
1198	Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications. 2012 , 13, 789-802	31
1197	A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction. 2012 , 30, 1684-9	35
1196	Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas. 2012 , 108, 395-402	40
1195	EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray. 2012 , 29, 401-5	59
1194	Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. 2012 , 69, 1063-9	35
1193	A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. 2012 , 70, 95-102	37
1192	Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma. 2012 , 460, 141-9	49
1191	Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines. 2012 , 138, 843-58	26
1190	In vivo targeting of HER2-positive tumor using 2-helix affibody molecules. 2012 , 43, 405-13	9
1189	Angiotensin-(1-7) inhibits epidermal growth factor receptor transactivation via a Mas receptor-dependent pathway. 2012 , 165, 1390-400	45
1188	A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen. 2012 , 24, 1847-55	21
1187	Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors. 2012 , 13, 267-79	17
1186	Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). 2012 , 13, 252-66	95

1185	Mutual repression by bantam miRNA and Capicua links the EGFR/MAPK and Hippo pathways in growth control. 2012 , 22, 651-7	71
1184	Simultaneous detection of multiple mutations in epidermal growth factor receptor based on fluorescence quenching of quantum dots. 2012 , 31, 558-61	7
1183	Discovery of novel EGFR tyrosine kinase inhibitors by structure-based virtual screening. 2012 , 22, 4004-9	18
1182	Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment. 2012 , 159, 281-9	69
1181	Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using ⁶⁴ Cu-labeled cetuximab positron emission tomography. 2012 , 103, 600-5	18
1180	ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective. 2012 , 32, 166-215	65
1179	Clinical Implications and Quality Assurance of Molecular Testing for EGFR-Targeting Agents in Colorectal Cancer. 2012 , 8, 42-50	4
1178	Chemoprevention for brain metastases. 2012 , 14, 63-9	9
1177	An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. 2012 , 69, 605-12	16
1176	A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton. 2012 , 30, 490-507	9
1175	The role of systemic treatment before, during, and after definitive treatment. 2013 , 46, 645-56	2
1174	Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?. 2013 , 70, 4131-40	16
1173	KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. 2013 , 133, 1259-65	141
1172	MicroRNAs targeting EGFR signalling pathway in colorectal cancer. 2013 , 139, 1615-24	44
1171	Vesicle Trafficking in Cancer. 2013 ,	1
1170	Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. 2013 , 71, 115-21	64
1169	Epidermal Growth Factor. 2013 , 497-499	1
1168	Lung cancer in never smokers: disease characteristics and risk factors. 2013 , 88, 494-503	91

1167	Effect of 3D matrix compositions on the efficacy of EGFR inhibition in pancreatic ductal adenocarcinoma cells. 2013 , 14, 3017-26	33
1166	Dissecting the EGFR-PI3K-AKT pathway in oral cancer highlights the role of the EGFR variant III and its clinical relevance. 2013 , 20, 43	24
1165	Metformin in lung cancer: rationale for a combination therapy. 2013 , 22, 1401-9	22
1164	Applications and limitations of oncogene mutation testing in clinical cytopathology. 2013 , 30, 284-97	35
1163	The quest to overcome resistance to EGFR-targeted therapies in cancer. 2013 , 19, 1389-400	684
1162	B-cell epitope peptide vaccination targeting dimer interface of epidermal growth factor receptor (EGFR). 2013 , 153, 33-40	8
1161	Activated PAR-2 regulates pancreatic cancer progression through ILK/HIF- α -induced TGF- β expression and MEK/VEGF-A-mediated angiogenesis. 2013 , 183, 566-75	35
1160	Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives. 2013 , 13, 1207-18	10
1159	Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 2013 , 8, 1381-97	6
1158	Immunity, inflammation and cancer: a leading role for adenosine. 2013 , 13, 842-57	468
1157	Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy. 2013 , 5, 199ra110	67
1156	Resistance to targeted therapies: a role for microRNAs?. 2013 , 19, 633-42	24
1155	Identification and characterization of proteins isolated from microvesicles derived from human lung cancer pleural effusions. 2013 , 13, 2125-34	66
1154	The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer. 2013 , 13, 599	43
1153	Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report. 2013 , 6, 508	8
1152	Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. 2013 , 32, 92	66
1151	Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody. 2013 , 40, 6737-45	24
1150	Tyrosine kinases inhibition by Imatinib slows progression in chronic anti-thy1 glomerulosclerosis of the rat. 2013 , 14, 223	4

1149	EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. 2013 , 154, 1269-84	379
1148	Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant. 2013 , 56, 7821-37	51
1147	MicroRNAs: Are they indicators for prediction of response to radiotherapy in breast cancer?. 2013 , 7, 59-64	4
1146	Epidermal growth factor receptor: pathway, therapies, and pipeline. 2013 , 35, 1282-303	66
1145	Comprehensive Immunomonitoring to Guide the Development of Immunotherapeutic Products for Cancer. 2013 , 241-258	1
1144	Expression and purification of chimeric peptide comprising EGFR B-cell epitope and measles virus fusion protein T-cell epitope in Escherichia coli. 2013 , 88, 7-12	6
1143	Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. 2013 , 73, 6770-9	61
1142	Label-free cell phenotypic assessment of the molecular mechanism of action of epidermal growth factor receptor inhibitors. 2013 , 3, 10370	17
1141	Increase of epidermal growth factor receptor expression in progression of GERD, Barrett, and adenocarcinoma of esophagus. 2013 , 58, 115-22	6
1140	Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. 2013 , 13, 241-55	44
1139	Sustained ERK [corrected] inhibition by EGFR targeting therapies is a predictive factor for synergistic cytotoxicity with PDT as neoadjuvant therapy. 2013 , 1830, 2659-70	27
1138	Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides. 2013 , 21, 27-43	63
1137	KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance. 2013 , 462, 39-46	26
1136	Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR. 2013 , 110, 1815-20	81
1135	Prospective comparison of freehand and electromagnetic needle tracking for US-guided percutaneous liver biopsy. 2013 , 24, 1682-9	20
1134	Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer. 2013 , 15, 61-72	12
1133	Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. 2013 , 203, 412-22	12
1132	Rationale and clinical use of multitargeting anticancer agents. 2013 , 13, 536-42	27

1131	Decreased expression of DAB2IP in pancreatic cancer with wild-type KRAS. 2013 , 12, 204-9	12
1130	Sensitive detection of BRAF V600E mutation by Amplification Refractory Mutation System (ARMS)-PCR. 2013 , 1, 3	57
1129	Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to anti-epidermal growth factor receptor antibody. 2013 , 13, 866-77	20
1128	The dynamic nature of the kinome. 2013 , 450, 1-8	75
1127	Tumor associated macrophages and neutrophils in tumor progression. 2013 , 228, 1404-12	280
1126	Sex differences in the drug therapy for oncologic diseases. 2012 , 411-42	48
1125	A cell-targeted photodynamic nanomedicine strategy for head and neck cancers. 2013 , 10, 1988-97	50
1124	Genomics and epigenomics of colorectal cancer. 2013 , 5, 205-19	25
1123	Relevance of molecular characterization of circulating tumor cells in breast cancer in the era of targeted therapies. 2013 , 13, 295-307	27
1122	Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. 2013 , 133, 2089-101	70
1121	Impact of genetic targets on therapy in head and neck squamous cell carcinoma. 2013 , 779, 165-77	4
1120	Tyrosine kinase signaling in fibrotic disorders: Translation of basic research to human disease. 2013 , 1832, 897-904	81
1119	Role of targeted agents in metastatic colorectal cancer. 2013 , 8, 83-96	52
1118	Cetuximab: still an option in the treatment of pancreatic cancer?. 2013 , 13, 791-801	14
1117	Erlotinib in the first-line treatment of non-small-cell lung cancer. 2013 , 13, 523-33	15
1116	Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors. 2013 , 4, 742-6	24
1115	On the nanotoxicity of PAMAM dendrimers: Superfect [®] stimulates the EGFR-ERK1/2 signal transduction pathway via an oxidative stress-dependent mechanism in HEK 293 cells. 2013 , 448, 239-46	26
1114	Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout. 2013 , 18, 11-24	7

1113	Improving outcomes in colorectal cancer: where do we go from here?. 2013 , 49, 2476-85	34
1112	EGFR tyrosine kinase inhibitors: difference in efficacy and resistance. 2013 , 15, 396-404	23
1111	Signal transduction and molecular targets of selected flavonoids. 2013 , 19, 163-80	26
1110	Repetitive dissociation from crocidolite asbestos acts as persistent signal for epidermal growth factor receptor. 2013 , 29, 6323-30	6
1109	Increased TGF- β s a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. 2013 , 19, 6751-65	111
1108	A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. 2013 , 31, 409-16	29
1107	Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. 2013 , 3, 658-73	489
1106	Molekulare Bildgebung und pathologische Diagnostik. 2013 , 19, 809-820	
1105	Effects of gefitinib, an epidermal growth factor receptor inhibitor, on human placental cell growth. 2013 , 122, 737-744	17
1104	Science to practice: Molecular targeting with SPECT/CT and MR imaging in oncology--integration of functional and structural imaging. 2013 , 267, 1-3	3
1103	Afatinib in advanced non-small-cell lung cancer. 2013 , 2, 493-504	
1102	Novel therapy based on camelid nanobodies. 2013 , 4, 1321-36	28
1101	Médecine personnalisée en cancérologie digestive. 2013 ,	
1100	Targeted therapy for non-small cell lung cancer. 2013 , 188, 907-12	19
1099	EGFR-ras-raf signaling in epidermal stem cells: roles in hair follicle development, regeneration, tissue remodeling and epidermal cancers. 2013 , 14, 19361-84	33
1098	Epidermal EGFR controls cutaneous host defense and prevents inflammation. 2013 , 5, 199ra111	151
1097	PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor. 2013 , 23, 636-42	13
1096	Prolidase directly binds and activates epidermal growth factor receptor and stimulates downstream signaling. 2013 , 288, 2365-75	25

1095	Functional genetic screens identify genes essential for tumor cell survival in head and neck and lung cancer. 2013 , 19, 1994-2003	59
1094	Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. 2013 , 31, 1931-8	300
1093	Directed evolution of a virus exclusively utilizing human epidermal growth factor receptor as the entry receptor. 2013 , 87, 11231-43	5
1092	Mapping of carboxypeptidase m in normal human kidney and renal cell carcinoma: expression in tumor-associated neovasculature and macrophages. 2013 , 61, 218-35	0
1091	Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. 2013 , 110, 8170-5	101
1090	Cross-talk between EGF and BMP9 signalling pathways regulates the osteogenic differentiation of mesenchymal stem cells. 2013 , 17, 1160-72	65
1089	MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1). 2013 , 288, 9508-18	138
1088	Breast cancer. 2013 , 28-53	
1087	Chemical kinetic mechanistic models to investigate cancer biology and impact cancer medicine. 2013 , 10, 026004	2
1086	NEU3 sialidase is activated under hypoxia and protects skeletal muscle cells from apoptosis through the activation of the epidermal growth factor receptor signaling pathway and the hypoxia-inducible factor (HIF)-1 β . 2013 , 288, 3153-62	34
1085	Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. 2013 , 19, 3508-19	88
1084	Antiproliferative, cell-cycle dysregulation effects of novel asiatic acid derivatives on human non-small cell lung cancer cells. 2013 , 61, 1015-23	20
1083	Chemotherapy of advanced non-small-cell lung cancer: current landscape. 2013 , 3, 265-279	
1082	Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer. 2013 , 183-232	
1081	Gefitinib: re-emerging from the shadows. 2013 , 2, 423-437	
1080	Nicotine induces resistance to epidermal growth factor receptor tyrosine kinase inhibitor by β nicotinic acetylcholine receptor-mediated activation in PC9 cells. 2013 , 8, 719-25	30
1079	Association of epidermal growth factor receptor and K-Ras mutations with smoking history in non-small cell lung cancer patients. 2013 , 5, 495-498	11
1078	Preoperative treatment of locally advanced esophageal carcinoma (Review). 2013 , 43, 1745-53	5

1077	Autres biomarqueurs potentiels des anti-EGFR. 2013 , 177-191	
1076	Combination gefitinib and methotrexate compared with methotrexate alone to treat ectopic pregnancy. 2013 , 122, 745-751	19
1075	Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series. 2013 , 23, 658-62	16
1074	Sequential treatment of tyrosine kinase inhibitors and chemotherapy for EGFR-mutated non-small cell lung cancer: a meta-analysis of Phase III trials. 2013 , 6, 1771-7	7
1073	Challenges and opportunities for cancer vaccines in the current NSCLC clinical scenario. 2013 , 13, 2551-61	2
1072	The different radiosensitivity when combining erlotinib with radiation at different administration schedules might be related to activity variations in c-MET-PI3K-AKT signal transduction. 2013 , 6, 603-8	8
1071	Progress in molecular imaging in endoscopy and endomicroscopy for cancer imaging. 2013 , 4, 1-22	12
1070	Involvement of TRPC channels in lung cancer cell differentiation and the correlation analysis in human non-small cell lung cancer. 2013 , 8, e67637	53
1069	Activation of ErbB2 and Downstream Signalling via Rho Kinases and ERK1/2 Contributes to Diabetes-Induced Vascular Dysfunction. 2013 , 8, e67813	25
1068	Claudin-3 overexpression increases the malignant potential of colorectal cancer cells: roles of ERK1/2 and PI3K-Akt as modulators of EGFR signaling. 2013 , 8, e74994	32
1067	Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors. 2013 , 8, e81393	8
1066	Effectors of epidermal growth factor receptor pathway: the genetic profiling of KRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. 2013 , 8, e81628	72
1065	The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis. 2013 , 8, e65995	85
1064	A case of NUT midline carcinoma with no HPV infection, slight EWSR1 rearrangement and strong expression of EGFR. 2013 , 99, e152-e155	3
1063	Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities. 2013 , 6, 931-42	15
1062	Great challenges in molecular medicine: toward personalized medicine. 2013 , 1, 1	3
1061	In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features. 2013 , 7, 789-839	12
1060	[Current status of molecular targeted therapies in hepatocellular carcinoma]. 2013 , 61, 136-46	4

1059	In silico prediction of inhibition of promiscuous breast cancer resistance protein (BCRP/ABCG2). 2014 , 9, e90689	15
1058	Differential transcriptional effects of EGFR inhibitors. 2014 , 9, e102466	11
1057	Macrophages, Neutrophils, and Cancer: A Double Edged Sword. 2014 , 2014, 1-14	28
1056	EGF and EGFR genetic polymorphisms predict prognosis in locally advanced pharyngolaryngeal squamous cell carcinoma patients receiving postoperative concurrent chemoradiotherapy. 2014 , 7, 2197-204	8
1055	Prospects of Omics Based Molecular Approaches in Colorectal Cancer Diagnosis and Treatment in the Developing World: A Case Study in Cape Town, South Africa. 2014 ,	1
1054	Nanoparticle drug formulations for cancer diagnosis and treatment. 2014 , 19, 223-45	13
1053	Mechanisms of resistance to EGFR inhibitors in colorectal cancers. 2014 , 3, 511-520	
1052	Recent advances in immunotherapy for non-small-cell lung cancer. 2014 , 10, 352-7	13
1051	Chloroquine and hydroxychloroquine for cancer therapy. 2014 , 1, e29911	120
1050	How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer. 2014 , 19, 1046-55	17
1049	Overcoming resistance to EGF receptor tyrosine kinase inhibitors in EGFR-mutated NSCLC. 2014 , 3, 459-476	1
1048	New Therapies and Functional-Molecular Imaging. 2014 , 77-96	
1047	EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells. 2014 , 15, 1677-87	36
1046	EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition. 2014 , 33, 77	9
1045	Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy. 2014 , 110, 1221-7	20
1044	Epidermal growth factor receptor (EGFR) and prostaglandin-endoperoxide synthase 2 (PTGS2) are prognostic biomarkers for patients with resected colorectal cancer liver metastases. 2014 , 111, 749-55	19
1043	Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNzyme. 2014 , 3, e150	5
1042	Structure-based ensemble-QSAR model: a novel approach to the study of the EGFR tyrosine kinase and its inhibitors. 2014 , 35, 301-10	13

1041	Epidermal growth factor receptor could play a prognostic role to predict the outcome of nasopharyngeal carcinoma: A meta-analysis. 2014 , 14, 267-77	20
1040	Relationship of thyroid transcription factor 1 to EGFR status in non-small-cell lung cancer. 2014 , 21, 305-8	6
1039	Lentiviral vector-based therapy in head and neck cancer (Review). 2014 , 7, 3-9	5
1038	[Targeted therapy in locally and metastatic recurrent cervical cancers]. 2014 , 101, 748-55	1
1037	Gefitinib-induced interstitial pneumonia: A case report and review of the literature. 2014 , 7, 855-859	5
1036	Epidermal growth factor receptor gene expression evaluation in colorectal cancer patients. 2014 , 51, 358-362	4
1035	Severe infusion reactions to cetuximab occur within 1 h in patients with metastatic colorectal cancer: results of a nationwide, multicenter, prospective registry study of 2126 patients in Japan. 2014 , 44, 541-6	18
1034	Management of EGFR-mutant non-small-cell lung cancer patients after first-line reversible EGF receptor-tyrosine kinase inhibitors. 2014 , 3, 77-84	
1033	New Approaches in Immunotherapy for the Treatment of Lung Cancer. 2017 , 405, 1-31	6
1032	Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks. 2014 , 5, 5811	53
1031	Ultrafluorogenic Coumarin-Tetrazine Probes for Real-Time Biological Imaging. 2014 , 126, 7661-7664	55
1030	A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles. 2014 , 57, 9889-900	44
1029	The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment. 2014 , 18, 218-30	73
1028	Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. 2014 , 4, 246-57	82
1027	Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials. 2014 , 35, 11741-50	13
1026	Clinical significance of GAB2, a scaffolding/docking protein acting downstream of EGFR in human colorectal cancer. 2014 , 21 Suppl 4, S743-9	13
1025	Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer. 2014 , 111, 17995-8000	45
1024	Bisphosphonates inactivate human EGFRs to exert antitumor actions. 2014 , 111, 17989-94	47

1023	The Epidermal Growth Factor Receptor Inhibitor-Related Skin Toxicity Index (EGFRISTI): a new tool for grading and managing skin adverse reactions to epidermal growth factor receptor inhibitors. 2014 , 87, 311-9	6
1022	Targeting the epidermal growth factor receptor in solid tumors: focus on safety. 2014 , 13, 535-49	22
1021	Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced non-small cell lung cancer. 2014 , 37, 148-53	22
1020	Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man. 2014 , 44, 1083-98	3
1019	Causes and consequences of microsatellite instability in gastric carcinogenesis. 2014 , 20, 16433-42	52
1018	Cotargeting EGFR and autophagy signaling: A novel therapeutic strategy for non-small-cell lung cancer. 2014 , 2, 8-12	31
1017	Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management. 2014 , 2014, 734249	50
1016	The role of microRNAs in the regulation of apoptosis in lung cancer and its application in cancer treatment. 2014 , 2014, 318030	34
1015	GI-4000 in KRAS mutant cancers. 2014 , 23, 273-8	4
1014	Biomarkers in pharmacology and drug discovery. 2014 , 87, 172-88	45
1013	Rapid and sensitive phenotypic marker detection on breast cancer cells using surface-enhanced Raman scattering (SERS) imaging. 2014 , 51, 238-43	161
1012	The ABC of BTC: structural properties and biological roles of betacellulin. 2014 , 28, 42-8	17
1011	Diacylglycerol kinase β modulates oncogenic properties of lung cancer cells. 2014 , 16, 29-35	18
1010	Personalized Health Care (PHC) in Cancer. 2014 , 23-49	
1009	Cell therapies and regenerative medicine. 2014 , 8, 158-65	
1008	Ionizing radiation-inducible miR-494 promotes glioma cell invasion through EGFR stabilization by targeting p190B rhoGAP. 2014 , 1843, 508-16	35
1007	Functional Imaging in Oncology. 2014 ,	1
1006	EGFR analysis: current evidence and future directions. 2014 , 42, 984-92	32

1005	Epidermal growth factor receptor endocytic traffic perturbation by phosphatidate phosphohydrolase inhibition: new strategy against cancer. 2014 , 281, 2172-89	17
1004	Highly sensitive EGFR mutation detection by specific amplification of mutant alleles. 2014 , 96, 85-91	2
1003	Facile identification of dual FLT3-Aurora A inhibitors: a computer-guided drug design approach. 2014 , 9, 953-61	6
1002	Phénomène d'ADCC, polymorphismes du récepteur Fcγ et conséquences en termes de développement thérapeutique ciblé 2014 , 16, 112-119	
1001	Synthesis and anticancer activity evaluation of new 1,2,3-triazole-4-carboxamide derivatives. 2014 , 23, 2426-2438	48
1000	Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS. 2014 , 35, 1041-9	17
999	Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS. 2014 , 73, 749-57	21
998	Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors. 2014 , 32, 145-53	21
997	[Predictive biomarkers for tumor-relevant signaling pathways in molecular pathology]. 2014 , 35, 93-105	
996	Inferring therapeutic targets from heterogeneous data: HKDC1 is a novel potential therapeutic target for cancer. 2014 , 30, 748-52	23
995	Emerging opportunities for the combination of molecularly targeted drugs with radiotherapy. 2014 , 26, 266-76	11
994	An integrin β KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. 2014 , 16, 457-68	257
993	Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer. 2014 , 433, 284-9	51
992	Molecular Testing in Cancer. 2014 ,	1
991	Pharmacogenomics and Personalized Medicines in Cancer Treatment. 2014 , 55-90	
990	Combined EGFR and autophagy modulation impairs cell migration and enhances radiosensitivity in human glioblastoma cells. 2014 , 229, 1863-73	37
989	KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond. 2014 , 67, 1-9	30
988	Molecular alterations and biomarkers in colorectal cancer. 2014 , 42, 124-39	62

987	Over-expression of EGFR is closely correlated to poor prognosis in Tunisian patients with non-small cell lung adenocarcinoma. 2014 , 35, 256-68	9
986	Transcriptional regulation of tissue organization and cell morphogenesis: the fly retina as a case study. 2014 , 385, 168-78	11
985	Idiopathic Pulmonary Fibrosis. 2014 ,	1
984	Anticancer Activity of Pyrazole via Different Biological Mechanisms. 2014 , 44, 1333-1374	28
983	KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells. 2014 , 134, 2146-55	28
982	Optimization of Anti-EGFR Treatment of Advanced Colorectal Cancer. 2014 , 10, 263-271	1
981	Optimization of the Development of Old and New EGFR and MAP Kinase Inhibitors for Colorectal Cancer. 2014 , 10, 279-287	
980	EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC). 2014 , 86, 158-63	41
979	Preparation and Evaluation of (99m)Tc-Epidermal Growth Factor Receptor (EGFR)-Peptide Nucleic Acid for Visualization of EGFR Messenger RNA Expression in Malignant Tumors. 2014 , 55, 1008-16	11
978	A prospective observational study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK Trial. 2014 , 44, 383-7	6
977	Increasing cancer-specific gene expression by targeting overexpressed $\alpha 5 \beta 1$ integrin and upregulated transcriptional activity of NF- κ B. 2014 , 11, 849-58	8
976	Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. 2014 , 1, 75-86	65
975	Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. 2014 , 40, 917-26	103
974	MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. 2014 , 74, 1857-69	103
973	Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. 2014 , 4, 1269-80	326
972	Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors. 2014 , 88, 1189-203	38
971	A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. 2014 , 387, 505-21	84
970	Conjugation-free, visual, and quantitative evaluation of inhibitors on protein tyrosine kinases and phosphatases with a luminescent Tb(III) complex. 2014 , 406, 2957-64	9

969	Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase i study in Japanese patients with advanced solid malignancies and advanced breast cancer. 2014 , 32, 946-54	10
968	PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17. 2014 , 20, 744-53	117
967	Oncogene dependency and the potential of targeted RNAi-based anti-cancer therapy. 2014 , 461, 1-13	15
966	The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review. 2014 , 16, 390	21
965	LMO1 is a novel oncogene in colorectal cancer and its overexpression is a new predictive marker for anti-EGFR therapy. 2014 , 35, 8161-7	7
964	Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. 2014 , 12, 115	4
963	Peptide nucleic acid-mediated aggregation of reduced graphene oxides and label-free detection of DNA mutation. 2014 , 118, 6297-301	6
962	Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. 2014 , 25, 1756-1761	91
961	Advances in individualized and regenerative medicine. 2014 , 59, 7-12	6
960	Simple and efficient capture of EGFR-expressing tumor cells using magnetic nanoparticles. 2014 , 201, 144-152	23
959	Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases. 2014 , 83, 159-65	20
958	The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. 2014 , 53, 852-64	261
957	Ultrafluorogenic coumarin-tetrazine probes for real-time biological imaging. 2014 , 53, 7531-4	175
956	Tailoring Chimeric Ligands for Studying and Biasing ErbB Receptor Family Interactions. 2014 , 126, 2700-2704	6
955	Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. 2014 , 20, 3775-86	76
954	The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer. 2014 , 120, 2299-307	73
953	Genes and pathology of non-small cell lung carcinoma. 2014 , 41, 28-39	50
952	FGF receptors: cancer biology and therapeutics. 2014 , 34, 280-300	332

951	Epidermal growth factor receptor inhibitors: coming of age. 2014 , 21, 74-9	51
950	Tumor Microenvironment, Angiogenesis Biology, and Targeted Therapy. 2014 , 505-526	
949	Gene expression of growth factors and growth factor receptors for potential targeted therapy of canine hepatocellular carcinoma. 2014 , 76, 301-6	2
948	Molecular Target Treatment for Personalized Radiotherapy in Lung Cancer. 2014 , 390-405	
947	Tailoring chimeric ligands for studying and biasing ErbB receptor family interactions. 2014 , 53, 2662-6	21
946	In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non-small cell lung cancer cell lines. 2015 , 33, 239-49	18
945	The Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis From 9 Randomized Controlled Trials. 2015 , 94, e1400	6
944	Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer. 2015 , 12, 1219-24	9
943	Targeted Therapy in Solid Tumors: Lung Cancer. 2015 , 224-230	
942	GLP recruitment systems specifically select PPI and affinity-enhanced candidate proteins that interact with membrane protein targets. 2015 , 5, 16723	2
941	The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences. 2015 , 13, 287	14
940	Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. 2015 , 13, 217	30
939	Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck. 2015 , 20, 1393-403	5
938	Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. 2015 , 137, 2470-7	6
937	KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery. 2015 , 94, e1284	10
936	Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials. 2015 , 137, 409-19	18
935	An improved cell membrane chromatography method for the simultaneous screening of two epidermal growth factor receptor antagonists from radix scutellariae. 2015 , 38, 3145-3150	10
934	The distinctive nature of adenocarcinoma of the lung. 2015 , 8, 2399-406	12

933	Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR. 2015 , 8, 63-79	21
932	Patterns of epidermal growth factor receptor mutation in non-small-cell lung cancers in the Gulf region. 2015 , 3, 1371-1374	17
931	Synergistic Inhibitory Effects of Cetuximab and Cisplatin on Human Colon Cancer Cell Growth via Inhibition of the ERK-Dependent EGF Receptor Signaling Pathway. 2015 , 2015, 397563	18
930	Nucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical Sensing. 2015 , 15, 16281-313	100
929	Biodegradable Eri silk nanoparticles as a delivery vehicle for bovine lactoferrin against MDA-MB-231 and MCF-7 breast cancer cells. 2016 , 11, 25-44	12
928	EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells. 2015 , 10, e0130543	8
927	The c-MET Network as Novel Prognostic Marker for Predicting Bladder Cancer Patients with an Increased Risk of Developing Aggressive Disease. 2015 , 10, e0134552	11
926	Transactivation of ErbB Family of Receptor Tyrosine Kinases Is Inhibited by Angiotensin-(1-7) via Its Mas Receptor. 2015 , 10, e0141657	23
925	Cetuximab-conjugated iron oxide nanoparticles for cancer imaging and therapy. 2015 , 10, 3663-85	39
924	The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma. 2015 , 2015, 948267	
923	. 2015 ,	2
922	Introduction of the hybcell-based compact sequencing technology and comparison to state-of-the-art methodologies for KRAS mutation detection. 2015 , 58, 126-34	2
921	Should KRAS mutation still be used as a routine predictor of response to EGFR-TKIs in advanced non-small-cell lung cancer? A reevaluation based on meta-analysis. 2015 , 141, 1427-39	9
920	Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells. 2015 , 43, 42-60	104
919	Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer. 2015 , 14, 100	59
918	Pretreatment levels of the serum biomarkers CEA, CYFRA 21-1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients. 2015 , 4, 171	21
917	Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. 2015 , 10, 583-96	16
916	KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients. 2015 , 21, 1595-605	42

915	Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies. 2015 , 21, 3377-83	27
914	EGFR signaling in colorectal cancer: a clinical perspective. 2015 , 21	4
913	Molecular biosensors: promising new tools for early detection of cancer. 2015 , 1	3
912	A phase I study of volasertib combined with afatinib, in advanced solid tumors. 2015 , 76, 843-51	14
911	Mechanisms underlying skin disorders induced by EGFR inhibitors. 2015 , 2, e1004969	55
910	Gastric Cancer: New Drugs - New Strategies. 2014 , 1, 180-94	12
909	Cancers bronchiques non ĩpetites cellules mutĩs ou rĩarrangĩs : de la premiere ĩa ĩiĩe ligne. 2015 , 7, 497-505	
908	BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations: A Systematic Review and Meta-Analysis. 2015 , 94, e1263	14
907	Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer. 2016 , 108, djv394	36
906	Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. 2015 , 8, 40-6	14
905	IM-412 inhibits the invasion of human breast carcinoma cells by blocking FGFR-mediated signaling. 2015 , 34, 2731-7	10
904	Prevalence of K-Ras mutations in hepatocellular carcinoma: A Turkish Oncology Group pilot study. 2015 , 3, 1275-1279	11
903	Development and Characterization of the Recombinant Human VEGF-EGF Dual-Targeting Fusion Protein as a Drug Delivery System. 2015 , 26, 2481-96	7
902	EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface. 2015 , 34, 1375-83	27
901	Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy. 2015 , 14, 523-32	89
900	KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer. 2015 , 68, 265-9	11
899	Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies. 2015 , 400, 129-43	12
898	Immunohistochemical expression of receptor tyrosine kinase PDGFR-ĩc-Met, and EGFR in skull base chordoma. 2015 , 38, 89-98; discussion 98-9	12

897	Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair. 2015 , 42, 216-226	286
896	Enhancing tumor-specific intracellular delivering efficiency of cell-penetrating peptide by fusion with a peptide targeting to EGFR. 2015 , 47, 997-1006	10
895	Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients. 2015 , 21, 675-87	8
894	Prospective phase II trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer. 2015 , 30, 337-45	16
893	Current adjuvant therapeutic approaches for pancreatic cancer. 2015 , 32, 42-56	6
892	Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency. 2015 , 7, 440-50	16
891	Acquired resistance to EGFR tyrosine kinase inhibitor in A431 squamous cell carcinoma xenografts is mediated by c-Kit pathway transduction. 2015 , 36, 2993-9	5
890	Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metalloproteinase-9. 2015 , 36, 1091-7	23
889	Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy. 2015 , 34, 5582-92	29
888	Textbook of Cell Signalling in Cancer. 2015 ,	5
887	Ionizing radiation-inducible miR-30e promotes glioma cell invasion through EGFR stabilization by directly targeting CBL-B. 2015 , 282, 1512-25	29
886	Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial. 2015 , 11, 421-9	7
885	Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade. 2015 , 45, 1560-9	28
884	Growth Factors and Tyrosine Kinase Receptors. 2015 , 1-26	
883	Mechanisms of resistance to EGFR tyrosine kinase inhibitors. 2015 , 5, 390-401	257
882	The small GTPase ADP-Ribosylation Factor 1 mediates the sensitivity of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors. 2015 , 16, 1535-47	13
881	USP8: a novel therapeutic target for Cushing's disease. 2015 , 50, 292-6	10
880	Cadmium and proliferation in human uterine leiomyoma cells: evidence of a role for EGFR/MAPK pathways but not classical estrogen receptor pathways. 2015 , 123, 331-6	25

879	Cancer modelling in the NGS era - Part I: Emerging technology and initial modelling. 2015 , 96, 274-307	7
878	CNAPS in Therapy Monitoring. 2015 , 325-367	3
877	JNK signaling is converted from anti- to pro-tumor pathway by Ras-mediated switch of Warts activity. 2015 , 403, 162-71	45
876	Unravelling the connection between metabolism, cell growth and cancer. 2015 , 39, 59-63	
875	A phase 1 study of ABT-806 in subjects with advanced solid tumors. 2015 , 33, 671-8	29
874	Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials. 2015 , 36, 3471-82	29
873	Cannabis smoke can be a major risk factor for early-age laryngeal cancer--a molecular signaling-based approach. 2015 , 36, 6029-36	20
872	Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas. 2015 , 24, 345-62	1
871	Quantification of cell surface receptor expression in live tissue culture media using a dual-tracer stain and rinse approach. 2015 ,	
870	Tumor and Patient Characteristics of Individuals with Mismatch Repair Deficient Colorectal Cancer. 2015 , 91, 286-93	7
869	Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). 2015 , 21, 1078-86	53
868	Next Generation Sequencing in Cancer Research, Volume 2. 2015 ,	4
867	A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity. 2015 , 26, 64-73	3
866	Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib. 2015 , 26, 371-8	8
865	A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases. 2015 , 16, 377-82	4
864	Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 2015 , 21, 2975-83	51
863	EGFR regulates the development and microarchitecture of intratumoral angiogenic vasculature capable of sustaining cancer cell intravasation. 2015 , 17, 634-49	38
862	Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients. 2015 , 56, 849-55	9

861	Targeted therapy in cancer. 2015 , 76, 1113-32	89
860	Causal mechanisms and balancing selection inferred from genetic associations with polycystic ovary syndrome. 2015 , 6, 8464	203
859	Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor (EGFR)-positive malignancies. 2015 , 64, 1517-29	16
858	SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer. 2015 , 21, 4686-97	93
857	Integrin $\alpha 4$ Promotes Autocrine Epidermal Growth Factor Receptor (EGFR) Signaling to Stimulate Migration and Invasion toward Hepatocyte Growth Factor (HGF). 2015 , 290, 27228-27238	20
856	High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitors. 2015 , 16, 1605-19	5
855	Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations. 2015 , 154, 155-62	57
854	Prognostic significance of epidermal growth factor receptor overexpression in pancreas cancer and nodal metastasis. 2015 , 85, 174-8	11
853	A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells. 2015 , 195, 5077-87	10
852	Thieno[2,3-d]pyrimidine based derivatives as kinase inhibitors and anticancer agents. 2015 , 1, 33-41	34
851	Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant. 2015 , 104, 115-26	15
850	Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer. 2015 , 24, 1185-98	4
849	Panitumumab for the treatment of metastatic colorectal cancer: a review. 2015 , 7, 721-38	6
848	Modernizing Eligibility Criteria for Molecularly Driven Trials. 2015 , 33, 2815-20	59
847	Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention. 2015 , 16, e611-21	48
846	A drug carrier targeting murine uPAR for photodynamic therapy and tumor imaging. 2015 , 23, 116-126	12
845	EGF-receptor specificity for phosphotyrosine-primed substrates provides signal integration with Src. 2015 , 22, 983-90	30
844	New therapeutic perspectives in CCDC6 deficient lung cancer cells. 2015 , 136, 2146-57	35

843	Severe gastrointestinal bleeding in patients with locally advanced head and neck squamous cell carcinoma treated by concurrent radiotherapy and Cetuximab. 2015 , 141, 177-84	9
842	Histological and Molecular Subclassification of Pancreatic and Nonpancreatic Periampullary Cancers: Implications for (Neo) Adjuvant Systemic Treatment. 2015 , 22, 2401-7	8
841	Circulating Nucleic Acids in Early Diagnosis, Prognosis and Treatment Monitoring. 2015 ,	7
840	Sensitisation of human lung adenocarcinoma A549 cells to radiotherapy by Nimotuzumab is associated with enhanced apoptosis and cell cycle arrest in the G2/M phase. 2015 , 39, 146-51	9
839	Protein marker profiling in different T classification in laryngeal squamous cell carcinoma. 2015 , 37, 357-65	3
838	Engineering toxin-resistant therapeutic stem cells to treat brain tumors. 2015 , 33, 589-600	24
837	Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration. 2015 , 136, 182-94	27
836	In vitro HER2 protein-induced affinity dissociation of carbon nanotube-wrapped anti-HER2 aptamers for HER2 protein detection. 2015 , 140, 243-9	41
835	Anti-Epidermal Growth Factor Receptor (EGFR) Treatment in Patients with Metastatic Colorectal Cancer. 2016 ,	1
834	Erythropoietin ameliorates hyperglycemia in type 1-like diabetic rats. 2016 , 10, 1877-84	7
833	Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients. 2016 , 7, 22257-70	89
832	Synergistic Anticancer Effect of Tocotrienol Combined with Chemotherapeutic Agents or Dietary Components: A Review. 2016 , 17,	29
831	Specific inhibition of p110 β subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers. 2016 , 7, 68546-68558	7
830	Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options. 2016 , 2016, 6896024	17
829	Selective Sensing of Tyrosine Phosphorylation in Peptides Using Terbium(III) Complexes. 2016 , 2016, 3216523	9
828	Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. 2016 , 6, 21-30	7
827	The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer. 2016 , 17,	14
826	Nanoparticle and Targeted Systems for Colon Cancer Therapy. 2016 , 695-713	

825	Current Management Strategies in Breast Cancer by Targeting Key Altered Molecular Players. 2016 , 6, 45	12
824	Role of Receptor Tyrosine Kinase Signaling in Renal Fibrosis. 2016 , 17,	28
823	Biomarker Development in Targeting Cancer Epigenetic. 2016 , 123-142	
822	Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS. 2016 , 9, 557-65	15
821	Molecular targeting in combination with platinum-based chemoradiotherapy in head and neck cancer treatment. 2016 , 38 Suppl 1, E2173-81	5
820	Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experience. 2016 , 38, 1318-23	8
819	Involvement of cysteine-rich protein 61 in the epidermal growth factor-induced migration of human anaplastic thyroid cancer cells. 2016 , 55, 622-32	14
818	NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors. 2016 , 139, 171-6	34
817	Molecular docking, MM/GBSA and 3D-QSAR studies on EGFR inhibitors. 2016 , 128, 1163-1173	16
816	Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting. 2016 , 5, 31053	190
815	A novel cell-penetrating peptide suppresses breast tumorigenesis by inhibiting Eatenin/LEF-1 signaling. 2016 , 6, 19156	41
814	Tumour biomarkers: homeostasis as a novel prognostic indicator. 2016 , 6,	18
813	Image-based compound profiling reveals a dual inhibitor of tyrosine kinase and microtubule polymerization. 2016 , 6, 25095	5
812	Inflammation-Induced Esophageal and Colon Adenocarcinoma Formation in Animal Models: Mechanisms of Carcinogenesis and Prevention. 2016 , 64-77	
811	Exome sequencing reveals germline gain-of-function mutation in an adult with Lhermitte-Duclos disease. 2016 , 2, a001230	14
810	RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres. 2016 , 16, 825	21
809	New Pharmaceutical Agents in Oncology. 2016 , 1, 435-463	
808	Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors. 2016 , 21, 156-64	48

807	Use of monoclonal antibodies to detect specific mutations in formalin-fixed, paraffin-embedded tissue sections. 2016 , 53, 168-77	8
806	Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature. 2016 , 11, 197-200	5
805	Changes of serum amino acid profiles by an epidermal growth factor receptor mutation and benzo[<i>a</i>]pyrene in mouse lung tumorigenesis. 2016 , 5, 1182-1192	
804	Synthesis and evaluation of novel non-covalent binding quinazoline glycoside derivatives targeting the L858R and T790M variants of EGFR. 2016 , 6, 36857-36862	7
803	Involvement of aquaporin-3 in epidermal growth factor receptor signaling via hydrogen peroxide transport in cancer cells. 2016 , 471, 603-9	45
802	Computer-aided design, synthesis, and biological evaluation of new indole-2-carboxamide derivatives as PI3K/EGFR inhibitors. 2016 , 26, 2685-90	21
801	A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells. 2016 , 15, 1311-20	20
800	Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines. 2016 , 48, 45-54	29
799	KRAS mutation testing in colorectal cancer: the model for molecular pathology testing in the future. 2016 , 5, 73-80	
798	The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients. 2016 , 22, 755-61	2
797	Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3- <i>d</i>]pyrimidine derivatives targeting epidermal growth factor receptor. 2016 , 118, 276-89	25
796	Genetics of Melanoma. 2016 ,	1
795	MicroRNAs as Therapeutic Targets and Colorectal Cancer Therapeutics. 2016 , 937, 239-47	16
794	miR-134 inhibits non-small cell lung cancer growth by targeting the epidermal growth factor receptor. 2016 , 20, 1974-83	51
793	Clarifying the biological significance of the CHK2 K373E somatic mutation discovered in The Cancer Genome Atlas database. 2016 , 590, 4275-4286	5
792	Amphiregulin Confers Regulatory T Cell Suppressive Function and Tumor Invasion via the EGFR/GSK-3 β /Foxp3 Axis. 2016 , 291, 21085-21095	68
791	ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis. 2016 , 381, 23-30	43
790	Enhanced gefitinib-induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia-mutated kinase inhibition in non-small-cell lung cancer cells. 2016 , 107, 444-51	5

789	Clinical Implications and Future Perspectives of Circulating Tumor Cells and Biomarkers in Clinical Outcomes of Colorectal Cancer. 2016 , 9, 340-7	26
788	Non-coding RNAs in Colorectal Cancer. 2016 ,	5
787	Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors. 2017 , 19, 219-228	20
786	Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors. 2016 , 78, 271-80	2
785	Nrf2 but not autophagy inhibition is associated with the survival of wild-type epidermal growth factor receptor non-small cell lung cancer cells. 2016 , 310, 140-149	9
784	Autophagic degradation of epidermal growth factor receptor in gefitinib-resistant lung cancer by celastrol. 2016 , 49, 1576-88	17
783	Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status. 2016 , 138, 1516-27	12
782	Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab. 2016 , 15, 2175-86	30
781	Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 2016 , 1, e000088	69
780	Impact of Angiotensin I-converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Survival of Patients with NSCLC. 2016 , 6, 21359	20
779	Epidermal growth factor receptor and notch signaling in non-small-cell lung cancer. 2016 , 5, 3572-3578	28
778	Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry. 2016 , 11, 2501-2505	15
777	Liquid Profiling of Circulating Nucleic Acids as a Novel Tool for the Management of Cancer Patients. 2016 , 924, 53-60	1
776	Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer. 2016 , 9, 65	19
775	Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential. 2016 , 6, 31740	24
774	Zirkulierende Nukleinsäuren – ein neues Universum in der laboratoriumsmedizinischen Diagnostik. 2016 , 40,	0
773	Characterization of Interactions Between Taspine Derivate TPD7 and EGF Receptor by Cell Membrane Chromatography with Zonal Elution and Frontal Analysis. 2016 , 79, 1585-1592	4
772	Hydroxytyrosol, a product from olive oil, reduces colon cancer growth by enhancing epidermal growth factor receptor degradation. 2016 , 60, 519-29	45

771	A novel bispecific diabody targeting both vascular endothelial growth factor receptor 2 and epidermal growth factor receptor for enhanced antitumor activity. 2016 , 32, 294-302	7
770	Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. 2016 , 14, 119	11
769	A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole. 2016 , 5, 45	12
768	TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer. 2016 , 78, 361-7	14
767	Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis. 2016 , 98, 106-113	33
766	Emerging role of mTOR in the response to cancer therapeutics. 2016 , 2, 241-251	76
765	Hypoxia-Responsive Polymersomes for Drug Delivery to Hypoxic Pancreatic Cancer Cells. 2016 , 17, 2507-13	93
764	Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells. 2016 , 45, 286-92	9
763	The matricellular protein CCN1 suppresses hepatocarcinogenesis by inhibiting compensatory proliferation. 2016 , 35, 1314-23	36
762	The apoptotic effect of simvastatin via the upregulation of BIM in nonsmall cell lung cancer cells. 2016 , 42, 14-23	16
761	Blood-based biomarkers for diagnosis, prognosis and treatment of colorectal cancer. 2016 , 455, 26-32	50
760	The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways. 2016 , 291, 1029-52	50
759	Increasing efficiency for estimating treatment-biomarker interactions with historical data. 2016 , 25, 2959-29713	
758	Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. 2016 , 37, 127-40	8
757	Investigational drugs for treating anal cancer and future perspectives. 2016 , 25, 51-62	
756	Development of gelatin nanoparticles conjugated with phytohemagglutinin erythroagglutinating loaded with gemcitabine for inducing apoptosis in non-small cell lung cancer cells. 2016 , 4, 2444-2454	15
755	Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck. 2016 , 39, 396-406	21
754	Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. 2016 , 59, 468-79	160

753	Spectrum of EGFR gene mutations in Vietnamese patients with non-small cell lung cancer. 2016 , 12, 86-90	5
752	Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. 2016 , 27, 1055-1061	49
751	Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors. 2016 , 26, 1571-1575	19
750	Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines. 2016 , 110, 195-203	19
749	The Pitfalls of Companion Diagnostics: Evaluation of Discordant EGFR Mutation Results from a Clinical Laboratory and a Central Laboratory. 2016 , 18, 331-335	1
748	A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. 2016 , 34, 168-75	33
747	GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands. 2016 , 15, 251-63	17
746	Pharmacologic resistance in colorectal cancer: a review. 2016 , 8, 57-84	259
745	PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time. 2016 , 224, 77-85	254
744	Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status. 2016 , 11, 371-81	18
743	EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role?. 2016 , 99, 170-9	12
742	Development and evaluation of a single domain antibody against human epidermal growth factor receptor (EGFR). 2016 , 120, 59-64	10
741	A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans. 2016 , 18, 228-38	25
740	Rational Design of a Dephosphorylation-Resistant Reporter Enables Single-Cell Measurement of Tyrosine Kinase Activity. 2016 , 11, 355-62	13
739	Cytosolic PKM2 stabilizes mutant EGFR protein expression through regulating HSP90-EGFR association. 2016 , 35, 3387-98	32
738	Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer. 2016 , 97, 85-95	17
737	Phosphorylated epidermal growth factor receptor expression and KRAS mutation status in salivary gland carcinomas. 2016 , 20, 541-51	4
736	Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics. 2016 , 22, 461-76	21

735	Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies. 2017 , 56, 106-117	17
734	Asiatic acid inhibits lung cancer cell growth and by destroying mitochondria. 2017 , 7, 65-72	46
733	Synthesis of novel oleanolic acid and ursolic acid in C-28 position derivatives as potential anticancer agents. 2017 , 40, 458-468	24
732	Individualized Medicine in Ovarian Cancer: Are We There Yet?. 2017 , 144, 229-231	
731	Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811. 2017 , 97, 554-562	11
730	The Development of a Dimroth Rearrangement Route to AZD8931. 2017 , 21, 336-345	3
729	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. 2017 , 174, 145-172	19
728	Overexpression of FAM83H-AS1 indicates poor patient survival and knockdown impairs cell proliferation and invasion via MET/EGFR signaling in lung cancer. 2017 , 7, 42819	32
727	Novel biotechnology approaches in colorectal cancer diagnosis and therapy. 2017 , 39, 785-803	13
726	Elevated COX-2 Expression Promotes Angiogenesis Through EGFR/p38-MAPK/Sp1-Dependent Signalling in Pancreatic Cancer. 2017 , 7, 470	42
725	MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor. 2017 , 133, 477-485	19
724	Development of a human epidermal growth factor derivative with EGFR-blocking and depleted biological activities: A comparative in vitro study using EGFR-positive breast cancer cells. 2017 , 103, 275-285	8
723	Cetuximab Prevents Methotrexate-Induced Cytotoxicity in Vitro through Epidermal Growth Factor Dependent Regulation of Renal Drug Transporters. 2017 , 14, 2147-2157	20
722	Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer. 2017 , 141, 731-743	15
721	EGFR gene mutation in gastrointestinal stromal tumours. 2017 , 71, 553-561	8
720	Uncommon EGFR mutations in advanced non-small cell lung cancer. 2017 , 109, 137-144	84
719	Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. 2017 , 79, 50-60	75
718	Reciprocal regulation between microRNAs and epigenetic machinery in colorectal cancer. 2017 , 13, 1048-1057	18

717	miR-370 regulates cell proliferation and migration by targeting EGFR in gastric cancer. 2017 , 38, 384-392	15
716	CT-guided aspiration lung biopsy for EGFR and ALK gene mutation analysis of lung cancer. 2017 , 13, 3415-3422	5
715	EGFR, Growth Factors. 2017 , 707-717	
714	Mechanisms of Molecular Carcinogenesis Volume 2. 2017 ,	1
713	Cetuximab-conjugated nanodiamonds drug delivery system for enhanced targeting therapy and 3D Raman imaging. 2017 , 10, 1636-1646	22
712	Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance. 2017 , 8, 15617	25
711	A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. 2017 , 22, 1024-e89	15
710	An overall review of targeted therapy in solid cancers. 2017 , 7, 99-105	8
709	Sensitization of EGFR Wild-Type Non-Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib. 2017 , 16, 1634-1644	12
708	Influence of mucinous and necrotic tissue in colorectal cancer samples on KRAS mutation analysis. 2017 , 213, 606-611	3
707	Hypoxic proliferation requires EGFR-mediated ERK activation in human pulmonary microvascular endothelial cells. 2017 , 312, L649-L656	7
706	Hypoxia-induced proliferation of HeLa cells depends on epidermal growth factor receptor-mediated arginase II induction. 2017 , 5, e13175	8
705	A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer. 2017 , 17, 188	7
704	Predictive biomarkers along gastric cancer pathogenetic pathways. 2017 , 17, 417-425	22
703	EGFR gene copy number as a predictive/biomarker for patients with non-small-cell lung cancer receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis. 2017 , 65, 72-81	12
702	Contemporary Oral Oncology. 2017 ,	
701	Propofol enhances the cisplatin-induced apoptosis on cervical cancer cells via EGFR/JAK2/STAT3 pathway. 2017 , 86, 324-333	56
700	Conformational stability of the epidermal growth factor (EGF) receptor as influenced by glycosylation, dimerization and EGF hormone binding. 2017 , 85, 561-570	13

699	Toroidal Protein Adaptor Assembles Ferrimagnetic Nanoparticle Fibers with Constructive Magnetic Coupling. 2017 , 27, 1604532	3
698	Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. 2017 , 53, 61-69	77
697	Inhibition of lung cancer in diethylnitrosamine-induced mice by Rhizoma paridis saponins. 2017 , 56, 1405-1413	16
696	Neolbaconol inhibits angiogenesis and tumor growth by suppressing EGFR-mediated VEGF production. 2017 , 56, 1414-1426	31
695	Emerging Cancer Biomarkers for HNSCC Detection and Therapeutic Intervention. 2017 , 281-308	1
694	Targeted Therapy and Prevention of Endometrial Cancer. 2017 , 187-223	
693	Precision Molecular Pathology of Uterine Cancer. 2017 ,	2
692	MiR-146a functions as a small silent player in gastric cancer. 2017 , 96, 238-245	32
691	EGFR pathway subgroups in Chilean colorectal cancer patients, detected by mutational and expression profiles, associated to different clinicopathological features. 2017 , 39, 1010428317724517	9
690	Augmented O-GlcNAcylation of AMP-activated kinase promotes the proliferation of LoVo cells, a colon cancer cell line. 2017 , 108, 2373-2382	11
689	Novel Method Proposing Chemical Structures with Desirable Profile of Activities Based on Chemical and Protein Spaces. 2017 , 36, 1700075	1
688	Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines. 2017 , 32, 229-238	12
687	Novel diphenylthiazole derivatives with multi-target mechanism: Synthesis, docking study, anticancer and anti-inflammatory activities. 2017 , 75, 127-138	30
686	Biological and Molecular Characterization of Circulating Tumor Cells: A Creative Strategy for Precision Medicine?. 2017 , 82, 71-103	1
685	Identification of hypoxia-regulated angiogenic genes in colorectal cancer. 2017 , 493, 461-467	8
684	PET-Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors. 2017 , 12, 407-421	8
683	How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors. 2017 , 142, 131-151	30
682	Precision Oncology: Present Status and Perspectives. 2017 , 7-26	

681	Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactions. 2017 , 13, 953-972	91
680	Changes in cell junctions induced by inhibition of epidermal growth factor receptor in oral squamous cell carcinoma cells. 2017 , 14, 953-960	1
679	Clinical analysis of NSCLC patients reveals lack of association between EGFR mutation and TET1 downregulation. 2017 , 24, 373-380	5
678	Anti-EGFR antibody conjugated silica nanoparticles as probes for lung cancer detection. 2017 , 14, 3407-3412	10
677	EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management. 2017 , 5, 135-148	20
676	Drug therapy of advanced cutaneous squamous cell carcinoma: is there any evidence?. 2017 , 29, 129-135	26
675	Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples. 2017 , 17, 139	16
674	Epidermal growth factor receptor signaling promotes metastatic prostate cancer through microRNA-96-mediated downregulation of the tumor suppressor ETV6. 2017 , 384, 1-8	21
673	Clinical Pharmacokinetics and Pharmacodynamics of Afatinib. 2017 , 56, 235-250	81
672	Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance. 2017 , 64, 107-115	45
671	Mutant allele specific imbalance in oncogenes with copy number alterations: Occurrence, mechanisms, and potential clinical implications. 2017 , 384, 86-93	20
670	Cytosolic delivery of siRNA by ultra-high affinity dsRNA binding proteins. 2017 , 45, 7602-7614	5
669	Real-world experience of afatinib as a first-line therapy for advanced mutation-positive lung adenocarcinoma. 2017 , 8, 90430-90443	46
668	The Immune System's Contribution to the Clinical Efficacy of EGFR Antagonist Treatment. 2017 , 8, 575	20
667	A High-Affinity Repebody for Molecular Imaging of EGFR-Expressing Malignant Tumors. 2017 , 7, 2620-2633	20
666	Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. 2017 , 18,	65
665	Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms. 2017 , 18,	70
664	Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. 2017 , 23, 4675-4688	70

663	Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies. 2017 , 5, 101	38
662	Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. 2017 , 9,	628
661	2D-QSAR and 3D-QSAR Analyses for EGFR Inhibitors. 2017 , 2017, 4649191	16
660	Chemotherapy Plus Cetuximab versus Chemotherapy Alone for Patients with KRAS Wild Type Unresectable Liver-Confined Metastases Colorectal Cancer: An Updated Meta-Analysis of RCTs. 2017 , 2017, 8464905	10
659	Colorectal Cancer: From the Genetic Model to Posttranscriptional Regulation by Noncoding RNAs. 2017 , 2017, 7354260	27
658	Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells. 2017 , 8, 82773-82783	5
657	New Therapies in Vulvar Cancer. 2017 , 303-312	
656	Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. 2017 , 8, 109-125	34
655	Pyrosequencing analysis of KRAS codon 61 mutations in Thai patients with advanced colorectal cancer. 2017 , 9, 61-67	
654	Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting. 2017 , 17, 149	20
653	Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib. 2017 , 50, 2049-2058	11
652	Oxidative stress mediates an increased formation of vascular endothelial growth factor in human hepatocarcinoma cells exposed to erlotinib. 2017 , 8, 57109-57120	4
651	Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer. 2017 , 8, 22414-22432	32
650	Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib. 2017 , 8, 109068-109078	10
649	Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. 2017 , 8, 3980-4000	144
648	TRAF6 regulates EGF-induced cell transformation and cSCC malignant phenotype through CD147/EGFR. 2018 , 7, 17	15
647	Combined inhibition of EGFR and c-ABL suppresses the growth of fulvestrant-resistant breast cancer cells through miR-375-autophagy axis. 2018 , 498, 559-565	17
646	Amino acid starvation culture condition sensitizes EGFR-expressing cancer cell lines to gefitinib-mediated cytotoxicity by inducing atypical necroptosis. 2018 , 52, 1165-1177	8

645	Synthesis of stable benzimidazole derivatives bearing pyrazole as anticancer and EGFR receptor inhibitors. 2018 , 78, 158-169	36
644	Discovery of selective EGFR modulator to inhibit L858R/T790M double mutants bearing a N-9-Diphenyl-9H-purin-2-amine scaffold. 2018 , 26, 1810-1822	7
643	Enhanced anticancer effects of <i>Scutellaria barbata</i> D. Don in combination with traditional Chinese medicine components on non-small cell lung cancer cells. 2018 , 217, 140-151	18
642	Syndecan-1 Controls Lung Tumorigenesis by Regulating miRNAs Packaged in Exosomes. 2018 , 188, 1094-1103	26
641	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. 2018 , 3, e000299	24
640	Inhibition of SLC1A5 sensitizes colorectal cancer to cetuximab. 2018 , 142, 2578-2588	23
639	Tumor-Penetrating Peptide-Functionalized Redox-Responsive Hyperbranched Poly(amido amine) Delivering siRNA for Lung Cancer Therapy. 2018 , 4, 988-996	13
638	Cell death-based treatment of lung adenocarcinoma. 2018 , 9, 117	208
637	Encyclopedia of Signaling Molecules. 2018 , 1502-1502	
636	Encyclopedia of Signaling Molecules. 2018 , 1603-1603	
635	Challenging Standard-of-Care Paradigms in the Precision Oncology Era. 2018 , 4, 101-109	22
634	Intratumoral morphological heterogeneity can be an indicator of genetic heterogeneity in colorectal cancer. 2018 , 104, 76-81	6
633	Recombinant phosphatidylserine-binding nanobodies for targeting of extracellular vesicles to tumor cells: a plug-and-play approach. 2018 , 10, 2413-2426	64
632	Encyclopedia of Signaling Molecules. 2018 , 1653-1653	
631	Taxanes Hybrid Nanovectors: From Design to Physico-Chemical Evaluation of Docetaxel and Paclitaxel Gold (III)-PEGylated Complex Nanocarriers. 2018 , 35, 1700299	15
630	Selective EGF-Receptor Inhibition in 'CD4' T'Cells Induces Anergy and 'Limits' Atherosclerosis. 2018 , 71, 160-172	30
629	Disruption of ETV6 leads to TWIST1-dependent progression and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in prostate cancer. 2018 , 17, 42	11
628	A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint. 2018 , 7, e1466016	29

627	EGFR (ErbB) Signaling Pathways in Pancreatic Cancer Pathogenesis. 2018 , 383-408	
626	The receptor tyrosine kinase ERBB4 is expressed in skin keratinocytes and influences epidermal proliferation. 2018 , 1862, 958-966	13
625	Epidermal Growth Factor Receptor Regulation of Ewing Sarcoma Cell Function. 2018 , 94, 383-393	6
624	Emerging growth factor receptor antagonists for ovarian cancer treatment. 2018 , 23, 1-16	1
623	Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer. 2018 , 57, 455-473	11
622	Simultaneous determination of temperature and erlotinib by novel carbon-based sensitive nanoparticles. 2018 , 255, 986-994	17
621	A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of V β V α -T cells. 2017 , 7, e1375641	34
620	Targeting epidermal growth factor receptor co-dependent signaling pathways in glioblastoma. 2018 , 10, e1398	12
619	The combination of curcumin and 5-fluorouracil in cancer therapy. 2018 , 41, 1-13	53
618	High cholesterol in lipid rafts reduces the sensitivity to EGFR-TKI therapy in non-small cell lung cancer. 2018 , 233, 6722-6732	25
617	Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity. 2018 , 144, 330-348	16
616	A Novel Signaling Complex between TROY and EGFR Mediates Glioblastoma Cell Invasion. 2018 , 16, 322-332	7
615	CBX3/heterochromatin protein 1 gamma is significantly upregulated in patients with non-small cell lung cancer. 2018 , 14, e283-e288	31
614	Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer. 2018 , 58, 7-24	15
613	MicroRNAs as novel biomarkers for colorectal cancer: New outlooks. 2018 , 97, 1319-1330	83
612	Effect of double mutations T790M/L858R on conformation and drug-resistant mechanism of epidermal growth factor receptor explored by molecular dynamics simulations.. 2018 , 8, 39797-39810	9
611	Comparison of fully-automated radiosyntheses of [C]erlotinib for preclinical and clinical use starting from in target produced [C]CO or [C]CH. 2018 , 3, 8	8
610	Cardiovascular oncology: exploring the effects of targeted cancer therapies on atherosclerosis. 2018 , 29, 381-388	5

609	The synthesis of 4-arylamido-2-arylaminoimidazoles as potent EGFR T790M/L858R inhibitors for NSCLC. 2018 , 26, 6087-6095	6
608	Receptor Tyrosine Kinase-Targeted Cancer Therapy. 2018 , 19,	103
607	New drug developments in metastatic gastric cancer. 2018 , 11, 1756284818808072	14
606	Correlation between microsatellite instability and RAS gene mutation and stage III colorectal cancer. 2019 , 17, 332-338	5
605	Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer. 2018 , 1110, 35-53	12
604	Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All. 2018 , 1110, 113-131	12
603	Targeted Therapy of Colorectal Cancer Subtypes. 2018 ,	
602	Immunohistochemical investigation of prognostic biomarkers in resected colorectal liver metastases: a systematic review and meta-analysis. 2018 , 18, 217	8
601	Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold. 2018 , 61, 11372-11383	15
600	Clinical Proteomics in Colorectal Cancer, a Promising Tool for Improving Personalised Medicine. 2018 , 6,	22
599	EpCAM ectodomain EpEX is a ligand of EGFR that counteracts EGF-mediated epithelial-mesenchymal transition through modulation of phospho-ERK1/2 in head and neck cancers. 2018 , 16, e2006624	24
598	Prognostic value of and in resected non-small cell lung cancer: a systematic review and meta-analysis. 2018 , 10, 3393-3404	18
597	Role of Tyrosine Kinases in Gastrointestinal Malignancies. 2018 ,	
596	Functional Consequences and Clinical Significance of Tyrosine Kinase Inhibitors in Advanced Colorectal Cancer. 2018 , 115-140	
595	Targeted next-generation sequencing of cancer-related genes in thyroid carcinoma: A single institution's experience. 2018 , 16, 7278-7286	14
594	Significance of the epidermal growth factor receptor mutation status and differences among molecular subgroups in surgically resected lung microinvasive adenocarcinoma. 2018 , 16, 7057-7067	2
593	Mutations of RAS/RAF Proto-oncogenes Impair Survival After Cytoreductive Surgery and HIPEC for Peritoneal Metastasis of Colorectal Origin. 2018 , 268, 845-853	52
592	Pan-HER-targeted approach for cancer therapy: Mechanisms, recent advances and clinical prospect. 2018 , 439, 113-130	6

591	Augmented Cell Signaling by Natural Polyphenols and Flavonoids: Insights Into Cancer Cell Remodeling and Prevention. 2018 , 58, 213-244	2
590	Treatments That Block Proteins Involved in Cell Communication. 2018 , 65-109	
589	Current and future biomarkers in gastric cancer. 2018 , 103, 1688-1700	30
588	USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma. 2018 , 433, 186-198	32
587	Polyphenols in Colorectal Cancer: Current State of Knowledge including Clinical Trials and Molecular Mechanism of Action. 2018 , 2018, 4154185	65
586	A20 regulates canonical wnt-signaling through an interaction with RIPK4. 2018 , 13, e0195893	4
585	Surface microstructures are associated with mutational intratumoral heterogeneity in colorectal tumors. 2018 , 53, 1241-1252	4
584	Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work. 2018 , 16, 515-525	6
583	Exosome-mediated transfer of lncRNA RP11-838N2.4 promotes erlotinib resistance in non-small cell lung cancer. 2018 , 53, 527-538	56
582	Pan-Cancer Analysis Reveals the Functional Importance of Protein Lysine Modification in Cancer Development. 2018 , 9, 254	17
581	Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients. 2018 , 9, 360	7
580	Toward a Tiered Model to Share Clinical Trial Data and Samples in Precision Oncology. 2018 , 5, 6	9
579	Effects of Fullerenol Nanoparticles on Rat Oocyte Meiosis Resumption. 2018 , 19,	11
578	Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer. 2018 , 10, 88	36
577	NS1-binding protein radiosensitizes esophageal squamous cell carcinoma by transcriptionally suppressing c-Myc. 2018 , 38, 33	10
576	ALIX Regulates Tumor-Mediated Immunosuppression by Controlling EGFR Activity and PD-L1 Presentation. 2018 , 24, 630-641	53
575	The IGF pathway is activated in insulinomas but downregulated in metastatic disease. 2018 ,	4
574	Metastatic Colorectal Cancer: Role of Target Therapies and Future Perspectives. 2018 , 18, 421-429	29

573	EGFR gene copy number decreases during anti-EGFR antibody therapy in colorectal cancer. 2018 , 82, 163-171	1
572	The tyrosine phosphorylated pro-survival form of Fas intensifies the EGF-induced signal in colorectal cancer cells through the nuclear EGFR/STAT3-mediated pathway. 2018 , 8, 12424	18
571	HER1-based vaccine: Simultaneous activation of humoral and cellular immune response. 2018 , 45, 75-83	3
570	Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors. 2018 , 155, 316-336	30
569	Chemotherapy of malignancy. 2018 , 631-656	1
568	Role of Tocotrienols in Chemosensitization of Cancer. 2018 , 77-97	0
567	Targeting EGFR in Lung Cancer: Current Standards and Developments. 2018 , 78, 893-911	40
566	STAT3 as a Major Contributor to Chemoresistance. 2019 , 145-167	1
565	Severe first infusion reaction related to cetuximab in cancer patients in Arkansas. 2019 , 25, 1130-1134	1
564	Correlations Study Between F-FDG PET/CT Metabolic Parameters Predicting Epidermal Growth Factor Receptor Mutation Status and Prognosis in Lung Adenocarcinoma. 2019 , 9, 589	6
563	Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase Inhibitors. 2019 , 12, 1425-1431	13
562	Immune Resistance and EGFR Antagonists in Colorectal Cancer. 2019 , 11,	27
561	Investigating a tradable credit scheme with the system optimum theory. 2019 , 11, 168781401985139	1
560	Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor. 2019 , 9, 1193-1203	12
559	Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies. 2019 , 25, 6899-6908	42
558	A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy. 2019 , 21, 77	32
557	Calcium Regulates HCC Proliferation as well as EGFR Recycling/Degradation and Could Be a New Therapeutic Target in HCC. 2019 , 11,	2
556	Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer. 2019 , 21, 1010-1024	25

555	Fluorescence molecular imaging for identification of high-grade dysplasia in patients with head and neck cancer. 2019 , 97, 50-55	11
554	Expression, purification, and characterization of the native intracellular domain of human epidermal growth factor receptors 1 and 2 in Escherichia coli. 2019 , 103, 8427-8438	6
553	Prognostic value of EGFR 19-del and 21-L858R mutations in patients with non-small cell lung cancer. 2019 , 18, 3887-3895	12
552	Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. 2019 , 38, 41	37
551	Applications of SNAP-tag technology in skin cancer therapy. 2019 , 2, e103	2
550	Histone methyltransferase NSD2 mediates the survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling. 2019 , 40, 1067-1075	15
549	Internal enhancement of DNA damage by a novel bispecific antibody-drug conjugate-like therapeutics via blockage of mTOR and PD-L1 signal pathways in pancreatic cancer. 2019 , 8, 643-655	6
548	Treatment of AECHB and Severe Hepatitis (Liver Failure). 2019 , 273-370	
547	A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation. 2019 , 38, 211	9
546	The Open Chromatin Landscape of Non-Small Cell Lung Carcinoma. 2019 , 79, 4840-4854	13
545	A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy. 2019 , 79, 4315-4323	4
544	Nobiletin and Derivatives: Functional Compounds from Citrus Fruit Peel for Colon Cancer Chemoprevention. 2019 , 11,	54
543	Circadian (De)regulation in Head and Neck Squamous Cell Carcinoma. 2019 , 20,	19
542	The role of targeted therapy in thymic carcinoma. 2019 , 25, 1712-1718	3
541	A Cancer Stem Cell Perspective on Minimal Residual Disease in Solid Malignancies. 2019 , 31-49	1
540	Cancer Stem Cell Resistance to Targeted Therapy. 2019 ,	1
539	Acute Exacerbation of Chronic Hepatitis B. 2019 ,	
538	Revisiting Epidermal Growth Factor Receptor () Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. 2019 , 3,	27

537	Spectroscopic Characterization and Cytotoxicity Assessment towards Human Colon Cancer Cell Lines of Acylated Cycloartane Glycosides from <i>L. 2019</i> , 24,	4
536	Microfluidic Analysis for Separating and Measuring the Deformability of Cancer Cell Subpopulations. 2019 , 4, 8318-8323	2
535	LXR-mediated downregulation of EGFR suppress colorectal cancer cell proliferation. 2019 , 120, 17391-17404	4
534	Screening potential antagonists of epidermal growth factor receptor from <i>Marsdenia tenacissima</i> via cell membrane chromatography model assisted by HPLC-ESI-IT-TOF-MS. 2019 , 33, e4569	6
533	Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. 2019 , 9, 383	44
532	Quantification of EGFR family in canine mammary ductal carcinomas in situ: implications on the histological graduation. 2019 , 43, 123-129	1
531	Transcriptome Alterations in Liver Metastases of Colorectal Cancer After Acquired Resistance to Cetuximab. 2019 , 16, 207-219	6
530	CD317 Activates EGFR by Regulating Its Association with Lipid Rafts. 2019 , 79, 2220-2231	7
529	Partial agonistic effect of cetuximab on epidermal growth factor receptor and Src kinase activation in triple-negative breast cancer cell lines. 2019 , 54, 1345-1356	4
528	Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review. 2019 , 15, 61-69	15
527	The emerging role of cell-free DNA as a molecular marker for cancer management. 2019 , 17, 100087	200
526	Targeting slug-mediated non-canonical activation of c-Met to overcome chemo-resistance in metastatic ovarian cancer cells. 2019 , 9, 484-495	12
525	A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology. 2019 , 18, 91-101.e3	15
524	Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies. 2019 , 18, 823-833	14
523	Relationships among mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer. 2019 , 25, 808-823	17
522	EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. 2019 , 18, 845-855	30
521	Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC. 2019 , 10, 1275-1287	11
520	Retrospective study comparing anti-EGFR monoclonal antibody plus cisplatin-based chemoradiotherapy versus chemoradiotherapy alone for stage II-IVb nasopharyngeal carcinoma and prognostic value of EGFR and VEGF expression. 2019 , 44, 572-580	7

519	Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives. 2019 , 79, 633-645	22
518	Single-Domain Antibodies as Therapeutic and Imaging Agents for the Treatment of CNS Diseases. 2019 , 8,	23
517	Clinical development of targeted and immune based anti-cancer therapies. 2019 , 38, 156	93
516	Experimental Design in Signal Transduction. 2019 , 113-169	
515	Construction of prognostic microRNA signature for human invasive breast cancer by integrated analysis. 2019 , 12, 1979-2010	8
514	Modular design of nanobody-drug conjugates for targeted-delivery of platinum anticancer drugs with an MRI contrast agent. 2019 , 55, 5175-5178	20
513	Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances. 2019 , 27, 1159-1194	35
512	Systems analysis identifies potential target genes to overcome cetuximab resistance in colorectal cancer cells. 2019 , 286, 1305-1318	18
511	MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer. 2019 , 145, 748-762	16
510	An Overview, Current Challenges of Drug Resistance, and Targeting Metastasis Associated With Lung Cancer. 2019 , 21-38	
509	Zwitterionic near-infrared fluorophore-conjugated epidermal growth factor for fast, real-time, and target-cell-specific cancer imaging. 2019 , 9, 1085-1095	8
508	Epidermal growth factor receptor role in pancreatic cancer. 2019 , 295-324	1
507	Network pharmacology and RNA sequencing studies on triterpenoid saponins from for the treatment of breast cancer.. 2019 , 9, 41088-41098	2
506	Poor Prognosis With Coexistence Of T790M Mutation And Common -Activating Mutation In Non-Small Cell Lung Cancer. 2019 , 11, 9621-9630	3
505	The prognostic value of tumor mutation burden in -mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base. 2019 , 11, 4507-4515	14
504	Prognostic nomograms for predicting cause-specific survival and overall survival of stage I-III colon cancer patients: a large population-based study. 2019 , 19, 355	16
503	Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling. 2019 , 12,	0
502	. 2019 ,	1

501	EGFR mutation: novel prognostic factor associated with immune infiltration in lower-grade glioma; an exploratory study. 2019 , 19, 1184	19
500	Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression. 2019 , 38, 492	14
499	Diagnostic Significance of HRAS Mutations in Epithelial-Myoepithelial Carcinomas Exhibiting a Broad Histopathologic Spectrum. 2019 , 43, 984-994	34
498	The RTK Interactome: Overview and Perspective on RTK Heterointeractions. 2019 , 119, 5881-5921	31
497	Tumor Initiation Capacity and Therapy Resistance Are Differential Features of EMT-Related Subpopulations in the NSCLC Cell Line A549. 2019 , 21, 185-196	27
496	EGFR Mutations. 2019 , 477-486	2
495	Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis. 2019 , 145, 284-294	23
494	Sequential therapy of neoadjuvant biochemotherapy with cetuximab, paclitaxel, and cisplatin followed by cetuximab-based concurrent bioradiotherapy in high-risk locally advanced oral squamous cell carcinoma: Final analysis of a phase 2 clinical trial. 2019 , 41, 1703-1712	7
493	Necitumumab for the treatment of advanced non-small-cell lung cancer. 2019 , 15, 705-716	19
492	A novel prognostic signature of seven genes for the prediction in patients with thymoma. 2019 , 145, 109-116	9
491	Design, synthesis, in silico pharmacokinetics prediction and biological evaluation of 1,4-dihydroindeno[1,2-c]pyrazole chalcone as EGFR /Akt pathway inhibitors. 2019 , 163, 636-648	17
490	HER2-targeted therapy: an emerging strategy in advanced colorectal cancer. 2019 , 28, 29-38	16
489	Targeted therapies in pancreatic cancer: Promises and failures. 2019 , 120, 2726-2741	13
488	Pharmacophore modeling, 3D-QSAR, docking and ADME prediction of quinazoline based EGFR inhibitors. 2019 , 12, 4815-4839	19
487	Colorectal adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to EGFR-targeted monoclonal antibodies, cetuximab and panitumumab. 2020 , 146, 2194-2200	10
486	Growth Factors, Gastrointestinal. 2020 , 755-762	
485	Molecular dynamics simulation and 3D-pharmacophore analysis of new quinoline-based analogues with dual potential against EGFR and VEGFR-2. 2020 , 142, 94-113	8
484	EGFR-mediated autophagy in tumourigenesis and therapeutic resistance. 2020 , 469, 207-216	24

483	VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR-PI3K-AKT pathway. 2020 , 39, 1213-1230	23
482	RNA sequencing for research and diagnostics in clinical oncology. 2020 , 60, 311-323	34
481	EGFR signaling pathway occupies an important position in cancer-related downstream signaling pathways of Pyk2. 2019 , 44, 2	7
480	Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. 2020 , 31, 30-40	58
479	Targeting innate sensing in the tumor microenvironment to improve immunotherapy. 2020 , 17, 13-26	35
478	CD274 (PD-L1), CDKN2A (p16), TP53, and EGFR immunohistochemical profile in primary, recurrent and metastatic vulvar cancer. 2020 , 33, 893-904	6
477	Upregulation of SNX5 predicts poor prognosis and promotes hepatocellular carcinoma progression by modulating the EGFR-ERK1/2 signaling pathway. 2020 , 39, 2140-2155	17
476	Hsa_circ_0012152 and Hsa_circ_0001857 Accurately Discriminate Acute Lymphoblastic Leukemia From Acute Myeloid Leukemia. 2020 , 10, 1655	8
475	Relevance of EGFR Between Serum VEGF and MMP-9 in Primary Hepatocellular Carcinoma Patients with Transarterial Chemoembolization. 2020 , 13, 9407-9417	2
474	Advances in targeted therapy for esophageal cancer. 2020 , 5, 229	72
473	Optogenetic interrogation and control of cell signaling. 2020 , 66, 195-206	7
472	Human skin biomarkers relationship to response to treatment with tyrosine kinase inhibitors in advanced EGFR-mutated lung adenocarcinoma. 2020 , 11, 3243-3251	
471	Novel therapeutic approaches for gastrointestinal malignancies. 2020 ,	
470	Overexpression of β Adrenergic Receptors and the Suppressive Effect of β Adrenergic Receptor Blockade in Oral Squamous Cell Carcinoma. 2020 , 78, 1871.e1-1871.e23	2
469	TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target. 2020 , 11, 3660	19
468	Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. 2020 , 8, 179-191	20
467	Computational studies of potent covalent inhibitors on wild type or T790M/L858R mutant epidermal growth factor receptor. 2020 , 152, 105463	0
466	and mutations in metastatic colorectal cancer: future perspectives for personalized therapy. 2020 , 8, 192-205	18

465	The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers. 2020 , 21,	17
464	Towards the era of precision medicine in metastatic colorectal cancer. 2020 , 5,	
463	Erlotinib-Loaded Poly(ϵ -Caprolactone) Nanocapsules Improve In Vitro Cytotoxicity and Anticlonogenic Effects on Human A549 Lung Cancer Cells. 2020 , 21, 229	6
462	The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An Study. 2020 , 11, 524968	1
461	Epidermal Growth Factor Receptor: Key to Selective Intracellular Delivery. 2020 , 85, 967-1092	9
460	Cell Cycle and Factors Involved in Inhibition or Progression of Breast Cancer. 2020 ,	
459	Role of tyrosine kinases in bladder cancer progression: an overview. 2020 , 18, 127	9
458	A Case of Adenomyoepithelioma With a Pleomorphic Adenoma-Like Component of the Male Breast. 2021 , 29, 538-542	2
457	rhEGF Treatment Improves EGFR Inhibitor-Induced Skin Barrier and Immune Defects. 2020 , 12,	4
456	Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. 2020 , 12,	12
455	Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. 2020 , 63, 10726-10741	11
454	Inhibition of Brain Epidermal Growth Factor Receptor Activation: A Novel Target in Neurodegenerative Diseases and Brain Injuries. 2020 , 98, 13-22	14
453	Low sample volume origami-paper-based graphene-modified aptasensors for label-free electrochemical detection of cancer biomarker-EGFR. 2020 , 6, 32	22
452	Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. 2020 , 40, e292-e308	2
451	Risk factors for developing cardiac toxicities in cancer patients treated with panitumumab combination therapy. 2020 , 16, 1359-1370	3
450	Nomograms for predicting specific distant metastatic sites and overall survival of colorectal cancer patients: A large population-based real-world study. 2020 , 10, 169-181	15
449	Radiotherapy combined with gefitinib for patients with locally advanced non-small cell lung cancer who are unfit for surgery or concurrent chemoradiotherapy: a phase II clinical trial. 2020 , 15, 155	2
448	Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER Trial. 2020 , 19, 270-276	

447	Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. 2020 , 9,	9
446	Electrolyte Disorders Induced by Antineoplastic Drugs. 2020 , 10, 779	12
445	The novel long noncoding RNA CRART16 confers cetuximab resistance in colorectal cancer cells by enhancing ERBB3 expression via miR-371a-5p. 2020 , 20, 68	15
444	Targeted Delivery of In Into the Nuclei of EGFR Overexpressing Cells Modular Nanotransporters With Anti-EGFR Affibody. 2020 , 11, 176	9
443	Therapeutic effects of the PKR inhibitor C16 suppressing tumor proliferation and angiogenesis in hepatocellular carcinoma in vitro and in vivo. 2020 , 10, 5133	7
442	Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial. 2020 , 10, e030738	1
441	Preclinical Evaluation of Cetuximab and Benzoporphyrin Derivative-Mediated Intraperitoneal Photodynamic Therapy in a Canine Model. 2020 , 96, 684-691	2
440	Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells. 2020 , 9, 1777046	3
439	Does the Use of the "Proseek Multiplex Oncology I Panel" on Peritoneal Fluid Allow a Better Insight in the Pathophysiology of Endometriosis, and in Particular Deep-Infiltrating Endometriosis?. 2020 , 9,	3
438	Inhibition of ITGB1 enhance the anti-tumor effect of cetuximab in colorectal cancer cell. 2020 , 99, e20944	3
437	Effectiveness of Vigna unguiculata seed extracts in preventing colorectal cancer. 2020 , 11, 5853-5865	3
436	B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine. 2020 , 16, 1767-1791	5
435	Purpuric drug eruptions induced by EGFR tyrosine kinase inhibitors are associated with IQGAP1-mediated increase in vascular permeability. 2020 , 250, 452-463	2
434	Frequent EGFR expression/EGFR amplification and lack of activating mutation in testicular choriocarcinoma. 2020 , 70, 262-269	2
433	Development of amine-functionalized superparamagnetic iron oxide nanoparticles anchored graphene nanosheets as a possible theranostic agent in cancer metastasis. 2020 , 10, 862-877	6
432	Four generations of EGFR TKIs associated with different pathogenic mutations in non-small cell lung carcinoma. 2020 , 28, 861-872	6
431	Targeting Super-Enhancers via Nanoparticle-Facilitated BRD4 and CDK7 Inhibitors Synergistically Suppresses Pancreatic Ductal Adenocarcinoma. 2020 , 7, 1902926	14
430	A caffeic acid phenethyl ester analog inhibits the proliferation of nasopharyngeal carcinoma cells via targeting epidermal growth factor receptor. 2020 , 34, e22491	6

429	Potential tripeptides against the tyrosine kinase domain of human epidermal growth factor receptor (HER) 2 through computational and kinase assay approaches. 2020 , 97, 107564	3
428	EGFR modulates complement activation in head and neck squamous cell carcinoma. 2020 , 20, 121	3
427	Generation of liver bipotential organoids with a small-molecule cocktail. 2020 , 12, 618-629	5
426	The role of growth factor receptors in viral infections: An opportunity for drug repurposing against emerging viral diseases such as COVID-19?. 2020 , 2, 296-303	33
425	Liquid Biopsy: Emergence of an Alternative Cancer Detection Method. 2020 , 13, 845-847	
424	Molecular Therapeutics in Development for Epidermolysis Bullosa: Update 2020. 2020 , 24, 299-309	26
423	Molecular pathways in vulvar squamous cell carcinoma: implications for target therapeutic strategies. 2020 , 146, 1647-1658	14
422	Modification of nitric oxide donors onto a monoclonal antibody boosts accumulation in solid tumors. 2020 , 583, 119352	
421	p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer. 2020 , 19, 956-965	1
420	Clinical performance evaluation of the IdyllaEGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer. 2020 , 20, 275	7
419	Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?. 2020 , 86, 102023	19
418	A strategic review on the involvement of receptors, transcription factors and hormones in acne pathogenesis. 2021 , 41, 105-116	2
417	Clinical development of CAR T cell therapy in China: 2020 update. 2021 , 18, 792-804	19
416	Targeting pivotal inflammatory pathways in COVID-19: A mechanistic review. 2021 , 890, 173620	16
415	Protein kinases as targets for developing anticancer agents from marine organisms. 2021 , 1865, 129759	0
414	Dysregulated miR-137 and its target EGFR contribute to the progression of pituitary adenomas. 2021 , 520, 111083	0
413	Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP. 2021 , 124, 721-727	2
412	Rapid Screening for EGFR Inhibitor in Rhei Radix et Rhizoma by HTRF Assay Coupled with HPLC Peak Fractionation. 2021 , 87, 375-382	1

411	Peptide-functionalized delivery vehicles for enhanced cancer therapy. 2021 , 593, 120141	7
410	Cancer cell-targeted cisplatin prodrug delivery metabolic labeling and bioorthogonal click reaction. 2021 , 9, 1301-1312	4
409	Adenosine Signaling in the Tumor Microenvironment. 2021 , 1270, 145-167	4
408	Tumor Microenvironment. 2021 ,	
407	Therapy targeting angiogenic potential of tumor. 2021 , 113-139	
406	Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors. 2021 , 13, 1950264	6
405	Current progress, challenges and future prospects of indazoles as protein kinase inhibitors for the treatment of cancer.. 2021 , 11, 25228-25257	4
404	Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy. 2021 , 13, 1758835920949418	1
403	Site of Recurrence and Survival After Surgery for Colorectal Peritoneal Metastasis. 2021 , 113, 1027-1035	4
402	Multi-omics reveals novel prognostic implication of SRC protein expression in bladder cancer and its correlation with immunotherapy response. 2021 , 53, 596-610	1
401	Development of a sensitive UHPLC-MS/MS method for the pharmacokinetics study of a novel tyrosine kinase inhibitors, 1-[4-(4-{5-Chloro-4-[2-(propane-2-sulfonyl)-phenylamino]-pyrimidin-2-ylamino}-phenyl)-piperazin-1-yl]-propanone in rats. 2021 , 35, e5059	
400	MYC Up-regulation Is a Useful Biomarker for Preoperative Neoadjuvant Chemotherapy Combined With Anti-EGFR in Liver Metastasis from Colorectal Cancer. 2021 , 35, 203-213	2
399	Robust Principal Component Analysis based on Hypergraph Regularization for Sample Clustering and Co-characteristic Gene Selection. 2021 , PP,	1
398	Pre-clinical investigation of STAT3 pathway in bladder cancer: Paving the way for clinical translation. 2021 , 133, 111077	10
397	Aptamers for Targeted Therapy. 2021 , 129-178	
396	Quinazoline alpha-adrenoreceptor blockers as an adjunct cancer treatment: From bench to bedside. 2021 , 893, 173831	1
395	Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers. 2021 , 11, 614332	9
394	Allosteric Inhibition of the Epidermal Growth Factor Receptor. 2021 , 60, 500-512	1

393	Phase II study of nimotuzumab (TheraCim-hR3) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma. 2021 , 43, 1641-1651	1
392	Extensive functional evaluation of exon 20 insertion mutations of EGFR. 2021 , 152, 135-142	8
391	Immuno-toxicological evaluation of her1 cancer vaccine in non-human primates: a 6-month subcutaneous study. 2021 , 43, 283-290	0
390	Comparison of gefitinib-induced skin adverse reactions (SAR) in C57BL/6 and FVB/N mice. 2021 , 10, 334-344	
389	Predictive Value of EGFR-PI3K-AKT-mTOR-Pathway Inhibitor Biomarkers for Head and Neck Squamous Cell Carcinoma: A Systematic Review. 2021 , 25, 123-136	6
388	Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents. 2021 , 214, 113222	11
387	Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers. 2021 , 39, 1315-1323	1
386	Gefitinib reduces oocyte quality by disturbing meiotic progression. 2021 , 452, 152705	2
385	Glycogen Synthase Kinase-3 Beta Expression Correlates With Worse Overall Survival in Non-Small Cell Lung Cancer-A Clinicopathological Series. 2021 , 11, 621050	1
384	Image-based phenotypic profiling of a chemogenomic screening library identifies novel druggable targets in the EGFR-pathway.	
383	Systemic therapy in addition to cytoreduction and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: recent insights from clinical studies and translational research. 2021 , 12, S206-S213	1
382	Design and synthesis of 4-anilinoquinazolines as Raf kinase inhibitors. Part 1. Selective B-Raf/B-Raf and potent EGFR/VEGFR2 inhibitory 4-(3-hydroxyanilino)-6-(1H-1,2,3-triazol-4-yl)quinazolines. 2021 , 109, 104715	2
381	Evaluation of Benzamide-chalcone Derivatives as EGFR/CDK2 inhibitor: Synthesis, in-vitro Inhibition, and Molecular Modeling Studies. 2021 ,	0
380	La importancia de la determinaci3n del HER 2 en el c3ncer g3strico avanzado: a prop3sito de un caso cl3nico. 2021 , 36, 2-11	
379	The importance of Ras in drug resistance in cancer. 2021 ,	7
378	Copy Number Variation and Rearrangements Assessment in Cancer: Comparison of Droplet Digital PCR with the Current Approaches. 2021 , 22,	1
377	Analysis of the EGFR Amplification and CDKN2A Deletion Regulated Transcriptomic Signatures Reveals the Prognostic Significance of in Patients With Glioma. 2021 , 11, 551160	5
376	Utilizing Publicly Available Cancer Clinicogenomic Data on CBioPortal to Compare Epidermal Growth Factor Receptor Mutant and Wildtype Non-Small Cell Lung Cancer. 2021 , 13, e14683	

375	Inhibition of Liver Metastasis in Colorectal Cancer by Targeting IL-13/IL13R α Binding Site with Specific Monoclonal Antibodies. 2021 , 13,	2
374	Role of thyroid hormone-integrin α β -signal and therapeutic strategies in colorectal cancers. 2021 , 28, 24	4
373	Precision oncology in metastatic colorectal cancer - from biology to medicine. 2021 , 18, 506-525	27
372	A Nomogram for Predicting Multiple Metastases in Metastatic Colorectal Cancer Patients: A Large Population-Based Study. 2021 , 11, 633995	2
371	NMR Profiling of Identifies Cytotoxic Compounds against Cetuximab-Resistant Colon Cancer Cell Lines. 2021 , 26,	1
370	IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells. 2021 , 12, 520	5
369	Cellular and Molecular Mechanisms of Pristimerin in Cancer Therapy: Recent Advances. 2021 , 11, 671548	0
368	A rare presentation of panitumumab-involved interstitial lung disease: Spontaneous pneumomediastinum. 2021 , 10781552211017977	0
367	Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?. 2021 , 22,	4
366	STAMBP promotes lung adenocarcinoma metastasis by regulating the EGFR/MAPK signaling pathway. 2021 , 23, 607-623	1
365	Using Network Pharmacology and Molecular Docking to Explore the Mechanism of Shan Ci Gu () Against Non-Small Cell Lung Cancer. 2021 , 9, 682862	6
364	The Clinical Assessment of MicroRNA Diagnostic, Prognostic, and Theranostic Value in Colorectal Cancer. 2021 , 13,	3
363	An integrated droplet digital PCR gene chip for absolute quantification of nucleic acid. 2021 , 25, 1	0
362	Cav1/EREG/YAP Axis in the Treatment Resistance of Cav1-Expressing Head and Neck Squamous Cell Carcinoma. 2021 , 13,	2
361	Pan-cancer network disorders revealed by overall and local signaling entropy. 2021 , 13, 622-635	
360	Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. 2021 , 40, 184	53
359	Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations. 2021 ,	3
358	Pancreatic Adenocarcinoma Therapeutics Targeting RTK and TGF Beta Receptor. 2021 , 22,	4

357	Colorectal Cancer: From Genetic Landscape to Targeted Therapy. 2021 , 2021, 9918116	8
356	Molecular Pathways and Druggable Targets in Head and Neck Squamous Cell Carcinoma. 2021 , 13,	3
355	The Impact of Long-Term Antibiotic Therapy of Cutaneous Adverse Reactions to EGFR Inhibitors in Colorectal Cancer Patients. 2021 , 10,	4
354	4-Acetyl-Anthroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis. 2021 , 22,	3
353	Landscape of Current Targeted Therapies for Advanced Colorectal Cancer.	
352	Cetuximab in locally advanced head and neck squamous cell carcinoma: Biological mechanisms involved in efficacy, toxicity and resistance. 2021 , 164, 103424	3
351	Single-molecule fluorescence vistas of how lipids regulate membrane proteins. 2021 , 49, 1685-1694	2
350	Immune checkpoints inhibitors in metastatic squamous cell carcinoma of the vulva. 2021 , 17, 3133-3135	0
349	Overview of serum and tissue markers in colorectal cancer: a primer for radiologists. 2021 , 46, 5521-5535	2
348	Overexpression of pEGF improved the gut protective function of Clostridium butyricum partly through STAT3 signal pathway. 2021 , 105, 5973-5991	2
347	Survival of gefitinib treated advanced non-small cell lung cancer patients harbouring EGFR mutations. 2021 , 9, 171-174	
346	Epidermal growth factor receptor (EGFR) mutation testing is useful for primary lung cancer diagnosis and appropriate surgical resection: A case series. 2021 ,	
345	Immunotherapy for lung cancer: Focusing on chimeric antigen receptor (CAR)-T cell therapy. 2021 , 46, 100791	0
344	Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents. 2021 , 40, 344-354	2
343	Therapeutically effective covalent spike protein inhibitors in treatment of SARS-CoV-2. 2021 , 1-14	2
342	Scaffold Repurposing of In-House Small Molecule Candidates Leads to Discovery of First-in-Class CDK-1/HER-2 Dual Inhibitors: In Vitro and In Silico Screening. 2021 , 26,	1
341	Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities. 2021 ,	0
340	Improvements in the Synthesis of the Third-Generation EGFR Inhibitor Osimertinib. 2021 , 104, e2100066	

339	EGFR-targeted prodrug activation using bioorthogonal alkene-azide click-and-release chemistry. 2021 , 46, 116361	0
338	Investigation on the clinical efficacy and mechanism of compound kushen injection in treating esophageal cancer based on multi-dimensional network meta-analysis and in vitro experiment. 2021 , 279, 114386	2
337	Design, synthesis and biological evaluation of aminopyrimidine derivatives bearing a 4,5,6,7-tetrahydrothieno [3,2-c]pyridine as potent EGFR inhibitors. 2021 , 226, 113845	1
336	Antitumour immunity regulated by aberrant ERBB family signalling. 2021 , 21, 181-197	32
335	Activated epidermal growth factor receptor in ovarian cancer. 2009 , 149, 203-26	29
334	Signal Transduction Pathways as Therapeutic Targets in Cancer Therapy. 2010 , 37-83	2
333	Encyclopedia of Signaling Molecules. 2016 , 1-11	1
332	Regulation of Epidermal Growth Factor Receptor Signaling by Endocytosis in Normal and Malignant Cells. 2013 , 279-302	1
331	The MAPK Pathway in Melanoma. 2016 , 151-163	1
330	Lung Cancer Receptors and Targeting Strategies. 2019 , 229-268	1
329	Stratifying Cancer Therapies by Molecular Interactions and Imaging. 2017 , 315-358	1
328	Tumor Angiogenesis. 2009 , 39-50	2
327	Onkologika. 2016 , 583-619	1
326	Onkologika. 2017 , 597-639	1
325	Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. 2012 , 58, 263-268	4
324	Chapter 5:Targeting Dipeptidyl Peptidase-4 (DPP-4) and Fibroblast Activation Protein (FAP) for Diabetes and Cancer Therapy. 2011 , 118-144	4
323	Inhibition of human lung adenocarcinoma growth and metastasis by JC polyomavirus-like particles packaged with an SP-B promoter-driven CD59-specific shRNA. 2019 , 133, 2159-2169	4
322	Epidermal growth factor signaling through transient receptor potential melastatin 7 cation channel regulates vascular smooth muscle cell function. 2020 , 134, 2019-2035	4

321	The immunogenic potential of recurrent cancer drug resistance mutations: an in silico study.	1
320	IL-36 β drives skin toxicity induced by EGFR/MEK inhibition and commensal <i>Cutibacterium acnes</i> . 2020 , 130, 1417-1430	13
319	Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. 2008 , 118, 3574-81	84
318	FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice. 2012 , 122, 3211-20	87
317	TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. 2018 , 128, 2500-2518	48
316	Anticancer Effect of Radix Astragali on Cholangiocarcinoma In Vitro and Its Mechanism via Network Pharmacology. 2020 , 26, e921162	3
315	BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer. 2010 , 2, RRN1187	12
314	Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. 2009 , 4, e7464	172
313	1,9-Pyrazoloanthrones downregulate HIF-1 α and sensitize cancer cells to cetuximab-mediated anti-EGFR therapy. 2010 , 5, e15823	14
312	Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival. 2014 , 9, e91139	12
311	Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells. 2014 , 9, e97719	39
310	Validation of a Multiplex Allele-Specific Polymerase Chain Reaction Assay for Detection of KRAS Gene Mutations in Formalin-Fixed, Paraffin-Embedded Tissues from Colorectal Cancer Patients. 2016 , 11, e0147672	12
309	Local Epidermal Growth Factor Receptor Signaling Mediates the Systemic Pathogenic Effects of <i>Staphylococcus aureus</i> Toxic Shock Syndrome. 2016 , 11, e0158969	1
308	AR-dependent phosphorylation and phospho-proteome targets in prostate cancer. 2020 , 27, R193-R210	4
307	Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin. 2016 , 7, 47777-47793	25
306	Molecular driver alterations and their clinical relevance in cancer of unknown primary site. 2016 , 7, 44322-44329	3
305	Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature. 2016 , 7, 50575-50581	9
304	TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer. 2016 , 7, 59441-59457	5

303	Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials. 2017 , 8, 7014-7024	8
302	DDR2 overexpression in urothelial carcinoma indicates an unfavorable prognosis: a large cohort study. 2016 , 7, 78918-78931	10
301	Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach. 2017 , 8, 3870-3880	30
300	RHBDD1 upregulates EGFR via the AP-1 pathway in colorectal cancer. 2017 , 8, 25251-25260	5
299	α 3-sialyltransferase type I regulates migration and peritoneal dissemination of ovarian cancer cells. 2017 , 8, 29013-29027	29
298	Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. 2017 , 8, 58709-58727	22
297	Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature. 2017 , 8, 57882-57888	8
296	Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation. 2017 , 8, 67592-67604	11
295	Quantitative network mapping of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapy. 2014 , 5, 3697-710	79
294	Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy. 2014 , 5, 6620-32	27
293	EGFR expression in patients with stage III colorectal cancer after adjuvant chemotherapy and on cancer cell function. 2017 , 8, 114663-114676	19
292	AMPK-mediated energy homeostasis and associated metabolic effects on cancer cell response and resistance to cetuximab. 2015 , 6, 11507-18	28
291	Combined inhibition of EGFR and c-ABL suppresses the growth of triple-negative breast cancer growth through inhibition of HOTAIR. 2015 , 6, 11150-61	58
290	ROS1 amplification mediates resistance to gefitinib in glioblastoma cells. 2015 , 6, 20388-95	14
289	A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations. 2015 , 6, 40815-21	14
288	Generation and characterization of a tetraspanin CD151/integrin β 1-binding domain competitively binding monoclonal antibody for inhibition of tumor progression in HCC. 2016 , 7, 6314-22	11
287	Gene therapy for colorectal cancer using adenovirus-mediated full-length antibody, cetuximab. 2016 , 7, 28262-72	8
286	Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurrence and prognostic significance. 2016 , 7, 39293-39301	30

285	The role of epithelial growth factors and insulin growth factors in the adrenal neoplasms. 2018 , 6, 253	8
284	Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy. 2020 , 27, 5274-5316	9
283	Targeting Anti-Cancer Active Compounds: Affinity-Based Chromatographic Assays. 2016 , 22, 5976-5987	19
282	Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers. 2019 , 19, 2128-2142	5
281	Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. 2020 , 20, 815-834	64
280	Expression and Evaluation of HuscFv Antibody -PE40 Immunotoxin for Target Therapy of EGFR-Overexpressing Cancers. 2018 , 16, e1743	3
279	Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. 2012 , 18, 6005-17	36
278	Molecular targeted therapy for hepatocellular carcinoma: current and future. 2013 , 19, 6144-55	60
277	Molecular targeting to treat gastric cancer. 2014 , 20, 13741-55	20
276	Clinical management of advanced gastric cancer: the role of new molecular drugs. 2014 , 20, 14537-58	36
275	Icotinib plus gemcitabine for metastatic pancreatic cancer: a case report. 2015 , 21, 3441-6	3
274	Evaluation of therapeutic effectiveness of (131)I-antiEGFR-BSA-PCL in a mouse model of colorectal cancer. 2016 , 22, 3758-68	11
273	Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. 2016 , 22, 6345-61	69
272	Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. 2016 , 22, 6944-54	47
271	Chloroquine promotes gefitinib-induced apoptosis by inhibiting protective autophagy in cutaneous squamous cell carcinoma. 2019 , 20, 4855-4866	7
270	The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer. 2010 , 2, 144-53	7
269	Integrating anti-EGFR therapies in metastatic colorectal cancer. 2013 , 4, 285-98	17
268	Radioembolization of hepatic tumors. 2014 , 5, 178-89	41

267	The relationship between BIM deletion polymorphism and clinical significance of epidermal growth factor receptor-mutated non-small cell lung cancer patients with epidermal growth factor receptor-tyrosine kinase inhibitor therapy: a meta-analysis. 2015 , 4, 792-6	8
266	Somatic DNA mutation analysis in targeted therapy of solid tumours. 2015 , 4, 125-38	16
265	Clinical Profile of Cutaneous Adverse Effects of Epidermal Growth Factor Receptor Inhibitors: A Prospective Observational Study of 76 Cases. 2019 , 10, 251-255	8
264	Efficacy and tolerability of nimotuzumab in combination with chemotherapy in recurrent and metastatic squamous cell carcinoma of head and neck at a cancer center in Northern India. 2020 , 57, 76-83	3
263	Tumor Growth Suppression and Enhanced Radioresponse by an Exogenous Epidermal Growth Factor in Mouse Xenograft Models with A431 Cells. 2015 , 47, 921-30	8
262	Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells. 2016 , 48, 355-64	4
261	Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 as a Novel Approach to Enhance Radiotherapy. 2011 , 1,	8
260	Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer. 2016 , 8, 1-7	3
259	Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action. 2010 , 1, 209-20	38
258	Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response. 2013 , 7, 611-5	12
257	Targeting metastatic upper gastrointestinal adenocarcinomas. 2011 , 2, 135-49	2
256	The role of epidermal growth factor receptor in diabetes-induced cardiac dysfunction. 2013 , 3, 5-9	26
255	Practical and molecular evaluation of colorectal cancer: new roles for the pathologist in the era of targeted therapy. 2010 , 134, 853-63	12
254	A Case of Sigmoid Colon Cancer in which Somatic Pain was Rapidly Alleviated after Panitumumab Administration Despite Tumor Progression. 2016 , 5, 38-41	2
253	Circulating Tumor Cells: A Window to Understand Cancer Metastasis, Monitor and Fight Against Cancers. 2015 , 4, 13-29	7
252	Epidermal growth factor receptor tyrosine kinase inhibitor versus placebo as maintenance therapy for advanced non- small-cell lung cancer: a meta-analysis of randomized controlled trials. 2013 , 14, 2413-9	17
251	Clinical outcomes and prognostic factors associated with the response to erlotinib in non-small-cell lung cancer patients with unknown EGFR mutational status. 2013 , 14, 3255-61	9
250	Clinical Implication of EGF A61G Polymorphism in the Risk of Non Small Cell Lung Adenocarcinoma Patients: A Case Control Study. 2015 , 16, 7529-34	4

- 249 Distribution of KRAS and BRAF Mutations in Metastatic Colorectal Cancers in Turkish Patients. **2016**, 17, 1175-9 6
- 248 Phosphorylation of iRhom2 at the plasma membrane controls mammalian TACE-dependent inflammatory and growth factor signalling. **2017**, 6, 66
- 247 Differential expression of miR-1, a putative tumor suppressing microRNA, in cancer resistant and cancer susceptible mice. **2013**, 1, e68 18
- 246 A network pharmacology approach to investigate the anticancer mechanism of cinobufagin against hepatocellular carcinoma via downregulation of EGFR-CDK2 signaling. **2021**, 431, 115739 1
- 245 Recent Publications on Medications and Pharmacy. **2008**, 43, 429-434
- 244 Molecular Targeted Therapies for HCC. **2009**, 589-614
- 243 [Off-label therapies in oncology]. **2009**, 150, 363-72
- 242 EGFR-Directed Monoclonal Antibodies. **2010**, 407-436
- 241 Molecular Biology of Cancer. **2009**, 1-26
- 240 EGFR Signaling Pathways in Pancreatic Cancer Pathogenesis. **2010**, 387-402
- 239 Expression of EGF/EGFR in body fluids and kidney tissues of rats with polycystic kidney disease and its significance. **2010**, 29, 14-18
- 238 Application of molecular medicine to pancreatic cancer. **2010**, 25, 35-45
- 237 Biologisch zielgerichtete medikamentöse Therapie. **2010**, 265-275
- 236 Targeting EGFR in HPV-Associated Cancer. **2010**, 211-234
- 235 Establishment of high throughput screening model for epidermal growth factor receptor tyrosine kinase inhibitor. **2010**, 29, 1349-1352
- 234 Carcinogenesis of Lung Cancer. **2010**, 203-212
- 233 Management of Advanced Non-small Cell Lung Cancer: Front Line Treatment. **2010**, 177-194
- 232 Pharmacologic Principles. **2010**, 159-199

- 231 Drug Reactions. **2010**, 297-319
- 230 Les facteurs de croissance et les récepteurs à activité tyrosine kinase. **2010**, 21-43
- 229 Principles of Cancer Therapy. **2010**, 621-628
- 228 Interacting Signaling Pathways in Mouse Skin Tumor Initiation and Progression. **2011**, 149-164
- 227 The Epidermal Growth Factor Receptor in Normal and Neoplastic Epithelia. **2011**, 113-129
- 226 MicroRNAs in Colorectal Cancer. **2011**, 107-133 1
- 225 Diagnosis and Multidisciplinary Treatment of Laryngeal Cancers. **2011**, 471-481
- 224 Pharmacogenetics and Pharmacogenomics II: Genetic Determinants of Drug Responses and Adverse Drug Reactions. **2011**, 443-452
- 223 Pyrosequencing Analysis for Detection of KRAS Mutation. **2011**, 143-152
- 222 Protein Therapeutics in Oncology. **2012**, 109-144 1
- 221 Clinical results with EGFR inhibitors in colorectal cancer. **2012**, 44-59
- 220 Modelling Biochemical Pathways with the Calculus of Looping Sequences. **2012**, 105-125
- 219 HGFK1 is associated with a better prognosis and reverses inhibition by gefitinib in NSCLC cases. **2012**, 13, 1457-61
- 218 Predictive Markers in Colon Cancer. **2013**, 1-23
- 217 Pancreatic Adenocarcinoma Surveillance Counterpoint: Europe. **2013**, 129-143
- 216 EGFR, Growth Factors. **2013**, 1-11
- 215 Pharmacological Treatment of Idiopathic Pulmonary Fibrosis. **2014**, 297-311
- 214 A Phase II Study of Erlotinib in Patients with Previously Treated Non-Small Cell Lung Cancer. **2014**, 03, 10-20

213 Molecular Testing in Pulmonary Tumors. **2014**, 211-228

212 Nimotuzumab in Treatment of Infiltrating Squamous Cell Carcinoma of Tongue. **2015**, 06, 141-145

211 Next-Generation Sequencing Applications in Head and Neck Oncology. **2015**, 401-422

210 Targeted Therapies For Intestinal Tumorigenesis. **2015**, 391-440

209 Next-Generation Sequencing in the Era of Cancer-Targeted Therapies: Towards the Personalised Medicine. **2015**, 39-55

208 Clinical study of nimotuzumab combined with chemotherapy in the treatment of late stage gastric cancer. **2014**, 15, 10273-6

10

207 Neoplasia of the Gastrointestinal Tract. 587-616

206 Histopathological Investigation of Nuclear Y-box Binding Protein-1 Expression in Salivary Gland Carcinoma. **2016**, 147, 102-104

205 Diagnosis and Multidisciplinary Treatment of Laryngeal Cancers. **2016**, 555-567

204 Histopathological Investigation of Nuclear Y-box Binding Protein-1 Expression in Salivary Gland Carcinoma. **2016**, 109, 349-359

203 Neuroendocrine Tumors of the Lung. **2016**, 153-178

202 Quantification of cell surface receptor in live tissue culture using a paired-agent stain and rinse approach. **2016**,

201 Targeted Therapies for Hepatocellular Carcinoma. **2016**, 513-529

200 Distribution of EGFR R521K Polymorphism in Different Iranian Ethnic Groups. **2016**, In Press,

199 Effect of intraperitoneal cetuximab administration on colonic anastomosis and early postoperative adhesion formation in a rat model. **2016**, 32, 157-61

0

198 Importance of Mutation Analysis in Anti-Cancer Therapy. 1-7

197 Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non-Small Cell Lung Cancer. **2016**, 7, 514-524

1

196 EGFR (ErbB) Signaling Pathways in Pancreatic Cancer Pathogenesis. **2017**, 1-26

0

- 195 Signal Transduction and Targeted Therapy for Gynecologic Cancer. **2017**, 23-67
- 194 Targeting epidermal growth factor receptor: An important strategy in oncology. **2017**, 8,
- 193 Antibody-Drug Conjugates in Head and Neck Cancer. **2017**, 60, 331-335
- 192 Expression of EGF receptors in canine prostate with proliferative inflammatory atrophy and carcinoma. **2017**, 47, 1
- 191 Hepatocellular Carcinoma. **2018**, 668-692.e9 1
- 190 Onkologika. **2018**, 645-691 1
- 189 Encyclopedia of Signaling Molecules. **2018**, 1593-1603
- 188 Proteomics for Cancer: Approaches and Challenges. **2019**, 343-368
- 187 Onkologika. **2019**, 817-875
- 186 Immunocytochemistry on Sputum Samples Predicts Prognosis of Lung Cancer. **2019**, 36, 38-43 1
- 185 Case report: Management of Progressive Lung Cancer Patients after First-Line EGFR Tyrosine Kinase Inhibitor Therapy. **2019**, 55, 239
- 184 Gold nanorod based delivery system could bring about superior therapy effect of Ramucirumab through direct cytotoxicity to cancer cell mediated by differential regulation of phagocytosis in gastric cancer cell.
- 183 Recent Development in the Biomarkers for the Gastric Cancer. **2020**, 115-138
- 182 Onkologika. **2020**, 671-732 1
- 181 Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer. **2020**, 1, 117-130
- 180 Gene rearrangement detection by next-generation sequencing in patients with non-small cell lung carcinoma. **2020**, 164, 127-132
- 179 Retrospective study on the clinicogenomic characteristics of EGFR mutant and wildtype NSCLC.
- 178 Docosahexaenoic Acid Inhibits Cell Proliferation through a Suppression of c-Myc Protein in Pancreatic Ductal Adenocarcinoma Cells. **2021**, 10,

177	Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy. 2020 , 21,	7
176	Fusobacterium nucleatum facilitates cetuximab resistance in colorectal cancer via the PI3K/AKT and JAK/STAT3 pathways.	0
175	Role of Her-2 in Gastrointestinal Tumours beyond Gastric Cancer: A Tool for Precision Medicine. 2021 , 3, 1-22	2
174	Application of graphical lasso in estimating network structure in gene set. 2020 , 8, 1556	0
173	Boosting of the enhanced permeability and retention effect with nanocapsules improves the therapeutic effects of cetuximab. 2020 , 17, 433-443	2
172	Lower Respiratory Tract. 2020 , 139-253	
171	Clinical Performance Evaluation Of The IdyllaEgfr Mutation Test On Formalin-Fixed Paraffin-Embedded Tissue Of Non-Small Cell Lung Cancer.	
170	Clinical Performance Evaluation of the IdyllaEgfr Mutation Test on Formalin-Fixed Paraffin-Embedded Tissue of Non-Small Cell Lung Cancer.	
169	Clinical biomarkers directing the management of patients with colon and lung cancer (beyond oncogene-addicted NSCLC). 2020 , 11, 3-6	1
168	Gold nanoparticles enhance antibody effect through direct cancer cell cytotoxicity by differential regulation of phagocytosis. 2021 , 12, 6371	6
167	The Therapeutic Potential of MAPK/ERK Inhibitors in the Treatment of Colorectal Cancer. 2021 ,	2
166	Diffuse scaly erythematous plaques in patient taking poziotinib. 2022 , 19, 4-6	1
165	Achievements in targeted therapies. 215-233	
164	Management of Colorectal Liver Metastases. 2021 , 553-574	0
163	Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy. 2009 , 3, 419-28	29
162	From bench to bedside: the growing use of translational research in cancer medicine. 2010 , 2, 1-18	48
161	The escalating role of epidermal growth factor receptor inhibitors in cancer management: clinical considerations for the health system pharmacist. 2010 , 35, 219-29	1
160	Evolving role of cetuximab in the treatment of colorectal cancer. 2009 , 1, 79-88	3

159	Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. 2010 , 10, 1-48	23
158	The Role of EGFR and HER2- Activating Mutations in Maxillary Sinus Cancer. 2012 , 7, 70-4	1
157	Early Detection of Serum Levels of HER-2 in Patients with Head and Neck Squamous Cell Carcinoma. 2013 , 25, 161-8	2
156	Activation of Keap1/Nrf2 signaling pathway by nuclear epidermal growth factor receptor in cancer cells. 2014 , 6, 649-63	16
155	Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis. 2015 , 12, 126-39	19
154	Cutaneous adverse reactions specific to epidermal growth factor receptor inhibitors. 2015 , 8 Spec Issue, 57-61	6
153	Integr(at)in(g) EGFR therapy in HNSCC. 2015 , 3, 338	
152	Cutaneous complications of molecular targeted therapy used in oncology. 2016 , 9, 19-25	8
151	Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma. 2017 , 7, 203-217	4
150	[EGFR and KRAS Gene Mutations in 754 Patients with Resectable Stage I-IIIa Non-small Cell Lung Cancer and Its Clinical Significance]. 2017 , 20, 617-622	3
149	[TKI Resistance for T790M Mutation]. 2015 , 18, 245-50	1
148	[Advances of molecular targeted drugs used in maintenance therapy of non-small cell lung cancer]. 2010 , 13, 1070-3	
147	[Epidermal growth factor receptor mutations and radiotherapy in non-small cell lung cancer]. 2013 , 16, 157-61	0
146	[Clinicopathological and prognostic significance of a panel of tumor biomarkers in lung adenocarcinoma: a tissue microarray study]. 2014 , 17, 243-53	
145	[Personalized targeted therapy for lung cancer]. 2013 , 16, C21-34	
144	Recent advances on the roles of epidermal growth factor receptor in psoriasis. 2019 , 11, 520-528	12
143	SOD2 Enhancement by Long-Term Inhibition of the PI3K Pathway Confers Multi-Drug Resistance and Enhanced Tumor-Initiating Features in Head and Neck Cancer. 2021 , 22,	
142	Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl)acrylamide derivatives as selective EGFR kinase inhibitors. 2022 , 118, 105471	1

141	SOD2 Enhancement by Long-Term Inhibition of the PI3K Pathway Confers Multi-Drug Resistance and Enhanced Tumor-Initiating Features in Head and Neck Cancer. 2021 , 22, 11260	0
140	Eruptive Seborrheic Keratoses Are Associated With a Co-Occurring Malignancy in the Majority of Reported Cases: A Systematic Review. 2021 , 12034754211035124	0
139	Colorectal Cancer Progression Is Potently Reduced by a Glucose-Free, High-Protein Diet: Comparison to Anti-EGFR Therapy. 2021 , 13,	0
138	An Early-Onset Advanced Rectal Cancer Patient With Increased KRAS Gene Copy Number Showed A Primary Resistance to Cetuximab in Combination With Chemotherapy: A Case Report. 2021 , 11, 755578	1
137	Onkologika. 2021 , 579-638	
136	Signaling pathways and their potential therapeutic utility in esophageal squamous cell carcinoma.. 2022 , 1	0
135	Pancreatic serous cystadenocarcinoma diagnosed with liver metastasis at 7 years after the resection of the primary serous neoplastic lesion.. 2022 , 1	
134	Association of Hypokalemia Incidence and Better Treatment Response in NSCLC Patients: A Meta-Analysis and Systematic Review on Anti-EGFR Targeted Therapy Clinical Trials.. 2021 , 11, 757456	0
133	Immunotherapeutic Strategies in Cancer and Atherosclerosis-Two Sides of the Same Coin.. 2021 , 8, 812702	
132	Predictive and therapeutic implications of a novel PLC β /SHP2-driven mechanism of cetuximab resistance in metastatic colorectal cancer.. 2022 ,	0
131	MiR-3918 Inhibits Tumorigenesis of Glioma via Targeting EGFR to Regulate PI3K/AKT and ERK Pathways.. 2022 , 72, 433	1
130	Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors.. 2022 , 27,	5
129	Development and Internal Validation of a Nomogram-Based Model to Predict Three-Year and Five-Year Overall Survival in Patients with Stage II/III Colon Cancer.. 2022 , 14, 225-236	
128	GLP2-GLP2R signal affects the viability and EGFR-TKIs sensitivity of PC9 and HCC827 cells.. 2022 , 22, 36	
127	AVL9 promotes colorectal carcinoma cell migration via regulating EGFR expression.. 2022 , 24, 1	0
126	A Comparative and Comprehensive Review of Antibody Applications in the Treatment of Lung Disease.. 2022 , 12,	0
125	Non-Coding RNAs in Colorectal Cancer: Their Functions and Mechanisms.. 2022 , 12, 783079	0
124	Hormonal Therapy for Gynecological Cancers: How Far Has Science Progressed toward Clinical Applications?. 2022 , 14,	10

123	Estimation of zorifertinib metabolic stability in human liver microsomes using LC-MS/MS.. 2022 , 211, 114626	3
122	Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies.. 2022 , 12, 804212	1
121	A novel dual-labeled small peptide as a multimodal imaging agent for targeting wild-type EGFR in tumors.. 2022 , 17, e0263474	1
120	Pharmacophore modeling, Virtual screening, Molecular docking and dynamics studies for the discovery of HER2-tyrosine kinase inhibitors: An in-silico approach. 2022 , 132531	1
119	Molecular methods for increasing the effectiveness of ovarian cancer treatment: a systematic review.. 2022 ,	2
118	Preclinical Identification of Sulfasalazine's Therapeutic Potential for Suppressing Colorectal Cancer Stemness and Metastasis through Targeting KRAS/MMP7/CD44 Signaling.. 2022 , 10,	0
117	Anticancer drug resistance: An update and perspective.. 2021 , 100796	17
116	Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?. 2021 , 13,	1
115	Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer. 2009 , 11, 737-47	3
114	MicroRNAs and Corresponding Targets in Esophageal Cancer as Shown and in Preclinical Models.. 2022 , 19, 113-129	1
113	EMT-mediated regulation of CXCL1/5 for resistance to anti-EGFR therapy in colorectal cancer.. 2022 ,	2
112	The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKK β and overcomes gefitinib resistance in non-small cell lung cancer.. 2022 ,	0
111	Recent Advancements in Mitochondria-Targeted Nanoparticle Drug Delivery for Cancer Therapy.. 2022 , 12,	2
110	In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer.	
109	Synthesis and Biological Activity of 3,9-Diazatetraasteranes as Novel EGFR Tyrosine Kinase Inhibitors. 2022 , 92, 446-456	0
108	Design, synthesis and evaluation of the Brigatinib analogues as potent inhibitors against tertiary EGFR mutants (EGFR and EGFR).. 2022 , 128729	
107	An RNA-cleaving threose nucleic acid enzyme capable of single point mutation discrimination.. 2021 ,	5
106	Prevalence of KRAS, PIK3CA, BRAF and AXIN2 gene mutations in colorectal cancer and its relationship with dental agenesis: a systematic review. 2021 , 71, e95595	

105 Proteolysis-targeting chimeras (PROTACs) in cancer therapy.. **2022**, 21, 99 4

104 Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection.. **2022**, 9, 847012 0

103 Bioluminescent RAPPID Sensors for the Single-Step Detection of Soluble Axl and Multiplex Analysis of Cell Surface Cancer Biomarkers.. **2022**, 1

102 Presentation_1.PDF. **2018**,

101 Table_1.XLSX. **2018**,

100 Table_2.XLSX. **2018**,

99 Table_3.XLSX. **2018**,

98 Table_4.XLSX. **2018**,

97 Table_5.XLSX. **2018**,

96 Table_6.XLSX. **2018**,

95 DataSheet_1.pdf. **2020**,

94 Table_1.xlsx. **2020**,

93 Table_2.xlsx. **2020**,

92 Table_3.xlsx. **2020**,

91 Table_4.xlsx. **2020**,

90 Table_5.xlsx. **2020**,

89 Table_6.xlsx. **2020**,

88 Table_7.xlsx. **2020**,

87	Table_8.xlsx. 2020 ,	
86	Table_1.DOCX. 2019 ,	
85	Table_2.DOCX. 2019 ,	
84	Data_Sheet_1.doc. 2020 ,	
83	Image_1.jpg. 2020 ,	
82	Image_2.jpg. 2020 ,	
81	Transcriptional and post-transcriptional regulation of checkpoint genes on the tumour side of the immunological synapse.. 2022 ,	0
80	Intractable perianal ulcerations developed after combined regimen targeting epidermal growth factor receptor and mesenchymal-epithelial transition factor in patients with non-small cell lung cancer.. 2022 ,	
79	Clinical management of metastatic colorectal cancer in the era of precision medicine.. 2022 ,	8
78	SBSN drives bladder cancer metastasis via EGFR/SRC/STAT3 signalling.. 2022 ,	0
77	Efficient synthesis and antitumor activity of novel oxazaphosphinane derivatives: X-ray crystallography, DFT study and molecular docking.. 2022 , 1-12	1
76	Predicting Novel Drug Candidates for Pancreatic Neuroendocrine Tumors via Gene Signature Comparison and Connectivity Mapping.. 2022 ,	0
75	4-aryl-N-phenylpyrimidin-2-amines Targeting EGFR-tyrosine kinase attenuated EGFR-expressing cell lines. 2022 , 100062	
74	Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology.	1
73	Drug repurposing: an emerging strategy in cancer therapeutics.	0
72	The Potential Tumor-Suppressor DHRS7 Inversely Correlates with EGFR Expression in Prostate Cancer Cells and Tumor Samples. 2022 , 14, 3074	
71	Cryo-electron Microscopic Analysis of Single-Pass Transmembrane Receptors.	1
70	Design, synthesis and biological evaluation of novel osimertinib derivatives as reversible EGFR kinase inhibitors. 2022 , 238, 114492	1

- 69 Current State of Targeted Therapy and Immunotherapy in Advanced Gastric and Gastro-oesophageal Cancers. **2022**, 18, 16
- 68 Biosimilar monoclonal antibodies in China: A patent review. **2022**, 13, 14503-14518
- 67 Proteomic analysis reveals key differences between squamous cell carcinomas and adenocarcinomas across multiple tissues. **2022**, 13, 0
- 66 Discovery and evaluation of cytosine N-isoflavones as novel EGFR/HER2 dual inhibitors. **2022**, 127, 105868 0
- 65 Protease-Activated Receptors in Health and Disease. 3
- 64 FMR1 promotes the progression of colorectal cancer cell by stabilizing EGFR mRNA in an m6A-dependent manner.
- 63 Hot-Spot-Specific Probe (HSSP) for Rapid and Accurate Detection of KRAS Mutations in Colorectal Cancer. **2022**, 12, 597
- 62 Visualizing Single-Nucleotide Variations in a Nuclear Genome Using Colocalization of Dual-Engineered CRISPR Probes. 1
- 61 Terminal Phenoxy Group as a Privileged Moiety of the Drug Scaffold: A Short Review of Most Recent Studies 2013-2022. **2022**, 23, 8874 1
- 60 Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: A Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. **2022**,
- 59 In-silico pharmacology against cancer of a novel phytosterol Dendrosterone isolated from plant *Dendrobium ochreatum*. **2022**, 4, 100149 1
- 58 *Kigelia africana* inhibits proliferation and induces cell death in stage 4 Neuroblastoma cell lines. **2022**, 154, 113584 1
- 57 Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients. **2022**, 172, 86-93 0
- 56 Design, synthesis and biological evaluation of novel macrocyclic derivatives bearing aniline pyrimidine scaffolds as EGFR-TKIs. **2022**, 75, 128970 0
- 55 In-Silico Pharmacology Against Cancer of a Novel Phytosterol Dendrosterone Isolated from Plant *Dendrobium Ochreatum*. 0
- 54 SNPs and Personalized Medicine: Scrutinizing Pathogenic Synonymous Mutations for Precision Oncology. **2022**, 185-195 0
- 53 Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC. **2022**, 12, 2360 0
- 52 Hypoxia-Inducible Expression of Annexin A6 Enhances the Resistance of Triple-Negative Breast Cancer Cells to EGFR and AR Antagonists. **2022**, 11, 3007 0

- 51 Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy. **2022**, 20, ○
- 50 Sphingosine 1-phosphate lyase facilitates cancer progression through converting sphingolipids to glycerophospholipids. **2022**, 12, ○
- 49 Topical GZ21T inhibits the growth of actinic keratoses in a UVB induced model of skin carcinogenesis. ○
- 48 Nanoencapsulation of tyrosine kinase inhibitors for oncological therapeutics. **2022**, 251-267 ○
- 47 Association between the risk of hepatitis virus-related hepatocellular carcinoma and EGF polymorphism: A PRISMA-compliant updated meta-analysis. **2022**, 101, e31280 ○
- 46 Oncogenes. 1-25 1
- 45 ERBB1/EGFR and JAK3 Tyrosine Kinases as Potential Therapeutic Targets in High-Risk Multiple Myeloma. **2022**, 2, 282-304 ○
- 44 Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies. 12, ○
- 43 Molecular characteristic analysis of non-small cell lung cancer patients at Nghe An Oncology Hospital. **2018**, 47, ○
- 42 In silico design of EGFR L858R/T790M/C797S inhibitors via 3D-QSAR, molecular docking, ADMET properties and molecular dynamics simulations. **2022**, 8, e11537 ○
- 41 FMR1 promotes the progression of colorectal cancer cell by stabilizing EGFR mRNA in an m6A-dependent manner. **2022**, 13, ○
- 40 The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC. **2022**, 156, 113959 ○
- 39 Non-small-cell lung cancer-associated gene mutations and inhibitors. **2022**, 6, 100076 ○
- 38 Current concepts of anti-EGFR targeting in metastatic colorectal cancer. 12, ○
- 37 Genetic and epigenetic characteristics of patients with colorectal cancer from Uruguay. **2023**, 241, 154264 ○
- 36 Comprehensive Review of Biomarkers for the Treatment of Locally Advanced Colon Cancer. **2022**, 11, 3744 ○
- 35 Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights. **2022**, 27, 8901 ○
- 34 RAMP: response-aware multi-task learning with contrastive regularization for cancer drug response prediction. ○

- 33 EGFR inhibition in EGFR -mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment. ○
- 32 Novel strategies to reverse chemoresistance in colorectal cancer. 1
- 31 Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with β -Substituent Electrophiles Targeting Cysteine. ○
- 30 The miRNA-185-5p/STIM1 Axis Regulates the Invasiveness of Nasopharyngeal Carcinoma Cell Lines by Modulating EGFR Activation-Stimulated Switch from E- to N-Cadherin. **2023**, 28, 818 ○
- 29 Decursin inhibits EGFR-ERK1/2 signaling axis in advanced human prostate carcinoma cells. ○
- 28 A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells. **2023**, 15, 57 ○
- 27 CD46 protects the bladder cancer cells from cetuximab-mediated cytotoxicity. **2022**, 12, ○
- 26 Uncovering the molecular mechanism of *Gynostemma pentaphyllum* (Thunb.) Makino against breast cancer using network pharmacology and molecular docking. **2022**, 101, e32165 ○
- 25 Targeted Therapies in Gallbladder Cancer: Current Status and Future Perspectives. **2023**, 291-316 ○
- 24 Integrative analysis of Iso-Seq and RNA-seq reveals dynamic changes of alternative promoter, alternative splicing and alternative polyadenylation during Angiotensin II-induced senescence in rat primary aortic endothelial cells. 14, ○
- 23 Sym004 anti-EGFR antibody mixture overcomes resistance to anti-EGFR antibodies in metastatic colorectal cancer. **2023**, 35-40 ○
- 22 Impact of signaling in the development pathway of genitourinary cancers. **2023**, 311-321 ○
- 21 ADAM12 promotes clear cell renal cell carcinoma progression and triggers EMT via EGFR/ERK signaling pathway. **2023**, 21, ○
- 20 Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. **2023**, 137-144 ○
- 19 Inhibition of SLC1A5 sensitizes colorectal cancer to cetuximab. **2023**, 161-166 ○
- 18 Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial. 13, ○
- 17 Targeted therapy based on ubiquitin-specific proteases, signalling pathways and E3 ligases in non-small-cell lung cancer. 13, ○
- 16 Cetuximab-conjugated PLGA nanoparticles as a prospective targeting therapeutics for non-small cell lung cancer. 1-16 ○

- 15 Analysis of the in vitro function and internalization ability of a humanized EGFR antibody AE01 expressed by Chinese hamster ovary cells. **2023**, 206, 106243 ○
- 14 VPS35 promotes cell proliferation via EGFR recycling and enhances EGFR inhibitors response in gastric cancer. **2023**, 89, 104451 ○
- 13 Hämatologische Neoplasien und solide Tumore. **2022**, 85-151 ○
- 12 Effect of Shan Zha (Hawthorn or Crataegus) on gastrointestinal cancer: A network pharmacology and molecular docking study. **2023**, ○
- 11 Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors. **2023**, 38, 100888 ○
- 10 Dermatological adverse drug reactions to tyrosine kinase inhibitors: a narrative review. ○
- 9 Prognostic significance of epidermal growth factor receptor and programmed cell death-ligand 1 co-expression in esophageal squamous cell carcinoma. ○
- 8 Blocking EREG/GPX4 Sensitizes Head and Neck Cancer to Cetuximab through Ferroptosis Induction. **2023**, 12, 733 ○
- 7 Recent updates on thienopyrimidine derivatives as anticancer agents. **2023**, 32, 659-681 ○
- 6 Recent findings on miR-370 expression, regulation and functions in cancer (Review). **2023**, 49, ○
- 5 Evodiamine-loaded rhEGF-conjugated bovine serum albumin nanoparticles alleviate indomethacin-associated gastric mucosal injury in male SD rats. **2023**, 82, 104345 ○
- 4 ALAN is a computational approach that interprets genomic findings in the context of tumor ecosystems. **2023**, 6, ○
- 3 Gastrointestinal injury induced by immunomodulators: A review article. **2023**, 16, 175628482311585 ○
- 2 Integrated in silico and in vitro rational design of oncogenic EGFR-derived specific monoclonal antibody-binding peptide mimotopes. **2023**, 21, ○
- 1 Topical GZ21T inhibits the growth of actinic keratoses in a UVB induced model of skin carcinogenesis. **2023**, 100206 ○